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Abstract
Discovery of Host-Microbiota Interactions
Connor Edwin Rosen
2021

The microbiota, comprising the trillions of microorganisms that colonize barrier
tissues, exert profound effects on host health and disease. Microbial effects on host
physiology have been illuminated by a wealth of sequencing-based approaches that
enumerate bacterial species, strains, genes, and products (collectively, “multi-omics”
approaches) at different tissue sites and in different human populations. Microbes may
influence local physiology at their site of residence, as well as having systemic effects
including perturbation of organism-wide metabolism, with wide-ranging consequences.
The molecular mechanisms by which microbes mediate both local and systemic effects,
however, remain mostly unclear. This is in part due to technological limitations in
profiling microbes at the scales necessary to characterize the thousands of unique strains
and species that comprise the collective human microbiota. The identification of specific
host pathways engaged or modulated by particular microbes will provide insight into how
the microbiota impacts host physiology, and suggest nodes of intervention for the
amelioration of microbiota-mediated disorders. In this thesis, I will describe a new
technological approach to profile direct microbial interactions with the host and how
discoveries enabled by this technique may shape our future understanding of hostmicrobe interactions.

1

In Chapter 1, I present a brief introduction to the microbiota, with a particular
focus of the intestinal microbiota, along with an introduction to the importance of
“functional profiling” to describe and classify the microbiota. The intestine is the most
densely populated organ by microbial cells, and includes a diverse range of
microenvironments that support a large diversity of microbes. Functional profiling may
support traditional multi-omics approaches to identify critical microbes or pathways in
host-microbe connection. In Chapter 2, I discuss selective pressures facing the intestinal
microbiota, to contextualize the functional profiling program of interest, an effort to
discovery direct cellular host-microbe interactions. In Chapter 3, I introduce yeast surface
display methodology and the design and creation of a library of human exoproteins that is
useful for interrogating binding partners of host exoproteins, validated and highlighted by
the discovery of the targets of human autoantibodies in autoimmune diseases. In Chapter
4, I present BASEHIT, a new technique for screening microbial cells using yeast surface
display libraries. I use BASEHIT to characterize the host binding patterns of hundreds of
microbes and describe the nature of interactions discovered as well as several particular
interactions of interest. In Chapters 5, I illustrate how BASEHIT may be applied to study
mechanisms of bacterial pathogenesis, through the lens of the causative agent of Lyme
disease, Borrelia burgdorferi.
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Chapter 1: Functional Profiling of the Microbiota

This chapter contains text that was first published essentially in this form in:
Rosen CE, Palm NW. Functional Classification of the Gut Microbiota: The Key to
Cracking the Microbiota Composition Code. Bioessays. 2017 Dec;39(12). doi:
10.1002/bies.201700032. Epub 2017 Oct 4. PMID: 28976007.

Abstract
The last decade has seen an explosion of research on the gut microbiota – the
trillions of microorganisms that colonize the human gut. It is clear that interindividual
diversity in microbiota composition plays an important role in determining susceptibility
to a wide variety of diseases and disorders. However, identifying the precise changes in
microbiota composition that play causal roles has remained a largely unrealized goal. Here,
we propose that functional classifications of microbes based on their interactions with and
effects on the host – particularly the host immune system – will illuminate the role of the
microbiota in shaping human physiology. We outline the benefits of ‘functional’
classification compared to phylogenetic classifications, and review current efforts at
functional classification of the microbiota. Finally, we outline a theoretical framework for
classifying host-microbiota interaction. Future advances enabling broader functional
classifications of the microbiota will revolutionize our understanding of the role of gut
microbes in both health and disease.

1. Introduction
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We are constitutively colonized by trillions of microorganisms at all mucosal and
barrier surfaces. These organisms, which are collectively referred to as the microbiota, span
all kingdoms of life, including fungi, viruses, archaea, protists, multicellular eukaryotes,
and bacteria (the most well understood and studied). The gastrointestinal tract contains the
largest number and greatest diversity of microbes: healthy humans harbor over 1014
bacterial cells. representing hundreds of species, which encode 150 times more genes than
the human genome.[1] The microbiota also exhibits extensive inter-individual diversity—
each individual contains a unique consortium of hundreds of bacterial species and strains,
and human gut microbial communities can vary between individuals at the phylum level,
which is the taxonomic level that separates humans from jellyfish.[1]
In the last decade, a torrent of evidence has illustrated the role of the intestinal
microbiota in various host processes including glucose tolerance,[2, 3] chronic malnutrition
and obesity,[4, 5, 6] autoimmune diseases including type I diabetes [7], inflammatory bowel
disease (IBD)
metabolism

[8]

[12]

, and others

[9, 10]

, inflammatory bone disease and osteoporosis

, neuronal development and function (the “gut-brain axis”)

enhancing the efficacy of various cancer therapeutics

[15, 16]

[11]

, drug

[6, 13, 14]

, and

. Despite this overwhelming

evidence for the role of microbiota composition in health and disease [17], it has remained
challenging to identify the precise changes in the microbiota that are responsible for
mediating these powerful effects, and this remains a major goal of the microbiota field.
Here, we will review the fundamental biological and technical roadblocks that have
contributed to this difficulty, and propose a theoretical framework for classifying members
of the microbiota that we believe will eventually allow us to achieve this goal. Critically,
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such an understanding is a necessary first step towards the rational development of
microbiota-targeted therapeutics.

2. Theoretical challenges in identifying ‘causal’ members of the microbiota
Over a century ago, Robert Koch proposed four criteria to establish a causal
relationship between a given microbe and disease. Koch’s postulates remain the ‘gold
standard’ for demonstrating the infectious origin of disease. In their most basic form,
Koch’s postulates require that a ‘causal’ microorganism fulfill four main criteria: (1) it
must be present in all sick individuals and absent in all healthy individuals; (2) it must be
isolated specifically from sick individuals; (3) administration of a pure culture of this
organism must cause disease in a previously healthy individual; and (4) this organism must
be re-isolated from the recipient where it caused disease and be shown to be identical to
the originally isolated organism. Since their original proposal, Koch’s postulates have been
repeatedly revised, taking into account phenomena such as healthy (asymptomatic)
carriers, insights from nucleic acid sequencing, and even adapted to explain the role of
specific virulence factors in disease (i.e., molecular Koch’s postulates) [18].
While Koch’s postulates have been invaluable for demonstrating the microbial
origin of infectious disease, applying these same principles to diseases that are potentially
controlled by the microbiota has remained challenging for a variety of reasons. First, the
role of the microbiota in disease often appears to depend on the relative balance of ‘good’
and ‘bad’ bacteria (or, in immunological terms, inflammatory versus immunoregulatory
bacteria) in the gut, rather than the specific presence of a single ‘pathogen’ (Figure 1.1a).
Therefore, the presence of a ‘bad’ bacterium can be countered by the effects of a ‘good’
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bacterium; this immediately violates the first of Koch’s postulates. This observation has
given rise to the theory of ‘dysbiosis’ – i.e., that ‘imbalances’ in microbiota composition
drive disease states (reviewed in [19, 20, 21]). Importantly, an individual bacterial taxon may
be ‘good’ in one situation, but ‘bad’ in another – for example, segmented filamentous
bacteria (SFB) can protect wild type mice from enteric infection, but also can exacerbate
autoimmune arthritis

[9, 22]

. These differences can dependent on a myriad of factors,

including host-genetics and health status, microbial location, and the surrounding microbial
community, further complicating efforts to describe a single bacterium as ‘good’ or ‘bad’,
and re-emphasizing the importance of a ‘balanced’ community. Second, it is highly
unlikely that complex diseases with diverse manifestations, such as inflammatory bowel
disease, are caused by a single ‘pathogenic’ organism. Instead, there are likely a variety of
indigenous microbes that contribute to disease susceptibility population wide. Third,
mouse models of disease have demonstrated that even phylogenetically divergent bacterial
species (e.g., one from the phylum Bacteroidetes and one from Firmicutes) can drive the
development of ostensibly identical disease states, such as bacterial-driven colitis (Figure
1.1b) [8]. Fourth, different strains of the same bacterial species can have divergent effects
on host physiology and disease susceptibility due to strain variation (Figure 1.1c)

[23]

.

Finally, even the same strain of bacteria may exert distinct effects on the host depending
on environment, location, or host-genetics – for example, metabolic effects of fecal
transplant into germ-free mice depend upon the recipient strain, even when the same donor
microbiota is used [24].
Taken together, these challenges suggest that a reevaluation of our current
approaches to understanding the role of the microbiota in disease may be necessary moving
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forward. Thus, we propose a renewed focus on microbial functions and posit that this
viewpoint, rather than a classical phylogeny-based approach, will eventually allow us to
‘crack’ the microbiota composition code.

3. Technical challenges in identifying ‘causal’ members of the microbiota:
Limitations of taxonomy-based microbiota profiling
In addition to these theoretical challenges, a number of technical challenges have
hampered current efforts to understand the role of the microbiota in disease. The
microbiome explosion has been driven largely by advances in next-generation sequencing
(NGS), which have enabled rapid, accurate, and inexpensive profiling of complex
microbial communities. By far the most common microbiota profiling method is based on
sequencing of the gene encoding the small subunit of ribosomal RNA (16S). 16S rRNA
gene sequencing has revolutionized the microbiome field by enabling nearly any lab to
determine the taxonomic composition of a given sample cheaply and easily. However, it
has also become clear that inherent limitations of 16S rRNA gene sequencing, and
taxonomic classifications in general, may limit its ability to reveal the role of the microbiota
in host physiology.
Taxonomic classifications of the microbiota are clearly useful for understanding
intra- and inter-individual diversity in microbial composition [25]. Furthermore, insofar as
function correlates with taxonomy, 16S rRNA gene sequencing can also begin to reveal
the role of particular microbes, as certain effects on the host can vary predictably across
taxonomic groups

[26]

. However, it has become increasingly clear that taxonomy alone is

often insufficient to determine microbial function. The most extreme case of this
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disconnect is in the case of strain variation—the observation that different strains of the
same species can have distinct, and sometimes opposite, effects on host physiology. For
example, distinct strains of the model symbiont Bacteroides fragilis vary broadly in their
effects on the host—some strains are tolerogenic due to the expression of the symbiosis
factor polysaccharide A (PSA)

[27]

, some ‘inert’ bacteria with no clear effects on host

physiology, and some highly pathogenic due to the expression of B. fragilis toxin (Figure
1.1c) [23].
Because of the limitations of taxonomy-based classification systems for studying
the microbiota, alternative approaches to defining the community composition and its
effects on the host are necessary. We suggest that a focus on the functions performed by
particular microbes will provide a classification scheme that will provide important insights
into how microbiota composition shapes host physiology. Below, we will address two
broad classes of ‘functional profiling’ of the microbiota. First, we will discuss ‘omics’based methods for functional classification of the microbiota, using metagenomics and
metabolomics as representative examples of this class of methodologies. Second, we will
discuss emerging methods for targeted functional profiling of the microbiota, with a focus
on an immunological profiling technique that we recently developed called IgA-Seq.

4. Microbial ‘functions’
Before we discuss functional profiling approaches, it is important to outline how
we define a microbial function. For the purpose of this perspective, we will use the term
‘function’ to refer to both activities of microbes (chemical or biological processes initiated
or performed by a microbe) as well as characteristics of microbes (intrinsic and/or passive
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microbial descriptors) that have a defined effect on host physiology. In other words,
microbial functions describe any feature of a microbe, active or passive, and qualitative or
quantitative, that impacts the host. Dozens of microbial functions with profound effects on
host physiology have been identified, and many more certainly remain to be discovered
and described – a non-comprehensive list of recently described functions are outlined
below. The known impacts of microbiota functions on the host have been excellently
reviewed elsewhere

[21, 28-30, 31]

. We will thus focus instead on how classifying the

microbiota based on these functions provides unique insights into the effects of the
microbiota on the host.

Treg induction

[23-26,28-30]

Th17 induction

[9,27,31,32]

Local IgA induction

[33]

Response to immunotherapy

[16,17]

Alteration of bone mass

[11]

Anti-microbial activity

[34,35]

Production of functional small molecule metabolites

[5,36]

LPS structure

[37,38]

Antigen-specific IgA coating

[8]

Niche colonization / localization

[39,40]

Niche modification

[41,42]
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Table 1.1: Known Functions of Members of the Microbiota

5. Functional classifications of the microbiota
We will discuss two classes of functional classifications (Figure 1.2b). First, we
will address ‘omics’-based approaches, such as metagenomics and metabolomics, which
enable functional classifications of the microbiota based on gene content and metabolic
functions. These approaches reveal the presence and abundance of previously identified
functions within a community through comparison to annotated databases. Second, we will
introduce a complementary class of functional profiling approaches that we refer to as
‘targeted’ functional profiling, which is typified by a technique that we recently developed
to profile microbial interactions with the immune system called IgA-Seq [8]. Importantly,
unlike omics approaches, targeted functional profiling approaches generate new functional
information (annotations) that can be assigned to specific microbial taxa.

6. ‘Omics-based’ Functional Profiling
Unlike 16S rRNA gene sequencing, which reveals simply ‘who is there’, systemslevel ‘omics’ approaches can begin to reveal ‘what they are doing’. A wide variety of
‘omics’ approaches have been applied to studies of host-microbiota interactions, including:
shotgun metagenomics—sequencing of the complete genetic material encoded by a
microbial community; metatranscriptomics—sequencing all of the RNA produced by a
microbial community; metaproteomics—profiling all of the proteins produced by a
microbial community; and metabolomics—profiling all of the small molecules produced
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by a microbial community [48].Many recent studies have also begun to employ multi-omics
approaches (i.e., integrating multiple omics approaches) to more completely characterize
the activities of microbial communities

[7, 49]

. Because omics approaches have been

excellently reviewed recently elsewhere [17, 48, 50, 51], we will largely restrict our discussion
to metagenomics and metabolomics as representative omics-based approaches since the
general strengths and limitations of these approaches apply to all ‘omics’ based approaches.
The ability of various ‘omics’ approaches to reveal the role of the microbiota in
human health and disease has been highlighted by a number of recent studies and reviews
[2, 5, 49, 52, 53]

. In particular, ‘omics’ approaches provide an unbiased assessment of microbial

functions and generate large amounts of data that can inform future hypothesis-based
experiments. Furthermore, recent advances in computational biology have greatly
improved the sensitivity, speed, and applicability of omics-based analyses of microbiome
data

[26, 54]

. Overall, the enormous utility of multi-omics approaches combined with

sophisticated computational analyses to reveal the roles of microbial communities in
human health and disease is now abundantly clear

[5, 41, 53, 55]

. However, a number of

inherent limitations of these approaches continue to restrict our ability to fully reveal the
role of the microbiota using ‘omics’ approaches alone.
The major limitation of ‘omics’-based profiling is its dependence on prior
functional annotations, which only exist for a minority of genes, proteins, and metabolites
encoded by host-associated microbial communities. For example, only 25% of observed
genes in the microbiome are annotated, and another 25% are annotated by homology only
[51, 56-58]

. Furthermore, the majority of annotated genes belong to large classes of gene

families that perform essential metabolic functions, whereas genes encoding proteins that
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mediate specific host-microbiota interactions remain mostly uncharacterized [51, 59]. These
well-understood metabolic gene families show low interindividual variability within the
human population and are therefore unlikely to contribute to differential disease
susceptibility among individuals

[57]

. Since the gut microbiome of an individual human

contains more than 150 times more genes than the human genome and each individual
possesses a unique microbiome

[56]

, determining the functions of all of these genes is a

daunting task. Finally, metagenomics only illustrates potential functions, as specific genes
may not be actively transcribed in certain in vivo settings [48]. To reveal realized functions,
metagenomics must be combined with metatranscriptomics or metaproteomics.
Current functional annotations of shotgun metabolomic data are even poorer than
functional annotations of metagenomic data. While targeted metabolomics approaches can
sensitively detect and quantify metabolites that are already well understood and have
known effects on host physiology, the physiological effects of the vast majority of
biosynthetic gene clusters and individual metabolites remain completely uncharacterized
[3, 17, 38, 60, 61]

. Indeed, at this stage it is difficult to even determine the total number of

metabolites produced by the gut microbiota, let alone to annotate all of their functions.
Metagenomics and metabolomics illustrate the strengths and limitations inherent in
‘omics’ approaches, which are shared by other methods such as metatranscriptomics and
metaproteomics (excellently reviewed elsewhere,

[17, 48]

). Most importantly, all of these

methods rely on prior annotations in order to assign functions to a given gene, protein or
metabolite.

7. New methods for ‘targeted’ functional classification
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We suggest that the limitations of taxonomic and omics-based profiling can be
overcome by combining these approaches with new methods for ‘targeted’ functional
profiling to enable assignment of new functions to specific bacterial taxa. Targeted
functional profiling methods should satisfy several criteria. First, they should assign
functions to taxa independent of prior annotations. Second, targeted functional profiling
approaches should be agnostic to taxonomic labels, and therefore identify taxonomically
divergent microbes that encode shared functions and distinguish between strains of the
same species that encode different functions. Third, targeted profiling should offer a
measure of bacterial importance that is independent of bacterial abundance; this can be
particularly useful for taxa that are rare in fecal samples, but may play outsized roles in
shaping host physiology.

7.1. Immunological profiling of the gut microbiota: IgA-Seq
One of the major mechanisms by which the gut microbiota influences host
physiology is through its interactions with and effects on the immune system

[28, 29]

. For

example, specific members of the murine gut microbiota that interact intimately with the
immune system in the gut, such as Helicobacter species and Segmented Filamentous
Bacteria, can exacerbate the development of inflammatory diseases in the intestine (e.g.,
Inflammatory Bowel Disease) and at distal sites (e.g., autoimmune arthritis) [9, 62]. A unique
feature of the immune response at mucosal surfaces is the production and secretion of
immunoglobulin A (IgA)

[28, 63]

. IgA is unique among antibody isotypes in that it is

primarily secreted into the intestinal lumen, where it can bind to and coat target bacteria.
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Effective IgA responses are essential to maintain a ‘healthy’ microbial composition in the
gut—in the absence of appropriate IgA responses, mice develop dysbiosis and exhibit
increased susceptibility to inflammatory disease [64, 65]. IgA can be produced through T-cell
independent or T-cell dependent mechanisms. T-dependent IgA is generally higher affinity
and targets more ‘highly pathogenic’ (invasive, aggressive, or damaging) microbes,
providing protective immunity

[63]

, while T-independent IgA is generally lower-affinity

antibody reactive against common microbial epitopes, which provide homeostatic
functions in controlling the extent of commensal interaction with the host epithelium and
mediating mucosal adhesion and selection [63, 65].
In order to identify specific bacterial taxa that interact intimately with the immune
system and, therefore, induce high-affinity IgA responses, we developed a functional
profiling technique called IgA-Seq. Briefly, IgA-Seq combines fluorescence activated cell
sorting and 16S rRNA gene sequencing to quantify Immunoglobulin A responses to the
intestinal microbiota in a taxa-specific manner (Figure 1.2a)

[8]

. IgA-Seq typifies the

‘targeted’ functional profiling approach by identifying specific microbes in the gut that
induce high-affinity, antigen-specific immune responses. Using IgA-Seq, we can focus in
on the bacterial species in each individual that likely play a major role in shaping host
immunity and susceptibility to inflammatory disease.
In the first application of this approach, we showed that IgA responses to the
microbiota in humans with inflammatory bowel disease marks putative disease-driving
bacteria that uniquely confer disease susceptibility when transplanted into germfree mice;
thus, IgA-coating identifies putative causal organisms in IBD that would not have been
identified simply using phylogenetic or omics approaches (Figure 1.1b)
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[8]

. IgA-Seq has

subsequently been used to identify microbes involved in both metabolic disease and
extraintestinal manifestations of IBD: IgA-coating was used to identify organisms that
contribute to the pathophysiology of severe malnutrition

[43]

and pathogenic strains of E.

coli present in a subset of Crohn’s disease patients that have a unique functional role in
inducing Th17 cells that may drive peripheral spondyloarthritis in these patients [66]. These
results suggest that IgA-Seq will be useful for identifying disease-modulating organisms
in a variety of diseases and disorders.
The example of IgA-Seq highlights several advantages of targeted functional
profiling as discussed above. IgA-Seq assigns function without reliance on prior
annotation. Second, IgA-Seq can distinguish between strains of the same species that differ
in their ability to induce an immune response, and identifies all bacterial species that are
able to do so – it is agnostic to taxonomic labels. Finally, it can identify bacteria that are at
low measurable abundance but play an important role in host physiology - for example,
segmented filamentous bacteria (SFB) are incredibly rare in mouse feces, but play a major
role in shaping both intestinal and extra-intestinal immunity [9, 22]; accordingly, SFB shows
the highest level of IgA coating in the gut by IgA-Seq [8].

7.2. Non-immunological targeted functional profiling
Another example of targeted functional profiling we recently described applies the
PRESTO-TANGO system for profiling GPCR activity[73] to systematically characterize the
GPCR-agonist activity of microbially derived metabolites. This “forward chemical genetic
screen”[74] revealed dozens of novel GPCR-active small molecules produced by individual
microbes in culture. These include widespread production of succinate, production of
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bioactive amines, and biotransformations of simple dietary amino acids. We then illustrated
the bioactivity of several of these metabolites to shape local (colonic motility) and systemic
(CNS phenethylamine accumulation) physiology in the host. This functional profiling
approach builds on similar investigations of individual metabolites[75], and again reflects
the ideal goals of a functional profiling approach – independence of taxonomic labels or
prior gene annotation, and application to bacterial isolates regardless of abundance.
Additional targeted functional profiling approaches continue to emerge and have
proven to be powerful tools to uncover the various functions of specific microbes when
combined with taxonomic or omics based profiling. For example, cell sorting based on
bacterial viability enables functional profiling of the ‘active’ fraction of the microbiota,
and revealed the impact of xenobiotics on specific microbial taxa from the gut microbiota
[67]

. Furthermore, a novel computational approach to the analysis of transcriptomic data

(Peak to Trough Ratio; PTR) allows for functional profiling of growth rates in a taxaspecific manner, which is particularly useful when following microbial responses to a
changing environment such as alterations in diet or during infection [68]. Finally, functional
metagenomics studies, where fragments of metagenomic DNA are expressed in a surrogate
host to identify genes involved in a specific bacterial activity or function, have enabled
discovery of unannotated genes that confer specific functions

[69]

– for example, the

identification of bacterial factors that improve in vivo fitness in a competitive setting [70].
One recent study employing a variation of functional metagenomics expressed predicted
nonribosomal peptide synthetase (NRPS) gene clusters identified in a wide range of gut
microbial genomes in genetically tractable model organisms (E. coli and B. subtilis),
identified new molecules produced from expression of these gene clusters, and confirmed
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their serine-protease inhibitory activity [71]. This study demonstrated a new function of the
microbiota that could be measured without reliance on prior annotation (while the authors
used bioinformatics and sequencing approaches to initially identify the NRPS gene
clusters, the function was not identified in an annotated database), could be agnostic to taxa
labels (each sequence expressed could be tied back to a single source strain, and distantly
related species could be identified through the same screen), and is independent of bacterial
abundance. This further illustrates how targeted functional profiling methods have the
ability to generate new biological hypotheses and discover new roles of the microbiota in
controlling host physiology.

7.3. Targeted functional profiling: Limitations and future applications
The above examples highlight the advantages of targeted functional profiling;
however, these approaches are, of course, not without their own limitations. Most notably,
these methods are generally lower-throughput than omics approaches, and are inherently
limited by their focus on a single function of interest (e.g., immune activation in the case
of IgA-Seq, or bacterial growth in the case of PTR). IgA-Seq, for example, is only useful
insofar as the disease or physiological function of interest is related to
inflammation/immunity at mucosal surfaces. Profiling of the complete spectrum of
functions of a microbial community will therefore require multiple, non-overlapping
functional analyses.
Future development of additional targeted profiling approaches promises to further
enable mechanistic studies and greatly expand research in the microbiota field. For
example, a recent study found that differences in LPS structure between members of the
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microbiota may predict immunostimulatory activity, and that these differences in activity
can influence the incidence of autoimmunity, building on a larger body of previous work
illustrating the effects of LPS modification on immunostimulatory activity

[41, 42, 72]

, and

suggesting that examination of essential, but variable, bacterial features is important for
determining disease susceptibility and may be a good candidate for targeted functional
profiling. Other phenotypes known or expected to be connected with host-microbe
interactions, such as spatial location within the gut and mucus association, should also
prove to be fruitful ground for high-throughput functional profiling of microbes.
An ultimate goal of targeted functional profiling will be to group gut microbes into
categories based on their effects on the host rather than their phylogeny or gene content.
Such a classification will be essential to elucidate shared bacterial mechanisms and host
pathways engaged by diverse groups of microbes that mediate specific effects on host
physiology. These common functions will provide strong candidate therapeutic axes for
treatment of microbiota-mediated diseases which may be universal rather than specific to
one bacterial species and/or subset of patients.

8. Conclusion
We are growing to appreciate that the complexity and diversity of the microbiota
can have wide-ranging and dramatic impacts on the host. However, we still lack the
understanding of how the precise composition of the microbiota drives various health and
disease outcomes – we have yet to “crack the microbiota composition code”. We propose
that functional classification of microbes, relying on outcomes rather than phylogeny, and
identifying easily-measurable correlates of function to enable high-throughput and rapid
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profiling of microbiota communities will be key to achieving this goal and moving towards
the rational development of microbiota-targeted therapeutics.
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Figure 1. Microbiota Composition has Complex Impacts on Disease Susceptibility. (A) Community
Composition Shapes Microbiota-Driven Disease. Rather than presence or absence of a single microbe being
linked to disease, it is now understood that microbiota-driven diseases can result from altered community
composition. Healthy individuals have a “balanced” microbiota, depicted as equal abundance of
immunoregulatory (blue) species and inflammatory species (red, orange, and yellow). Gain of a novel
inflammatory species (moving to the right) results in disease, despite the continued presence of the same
immunoregulatory microbes, while loss of a immunoregulatory species (moving to the left) also results in
disease, despite no new inflammatory phenotypes appearing. (B) Phylogentically Diverse Microbes Can
Cause Similar Phenotypes. Koch’s postulates require the causative agent of a disease be the same among all
afflicted individuals. However, it is known that a wide array of phylogenetically diverse microbes (depicted
as red bacteria at different branches of a mock phylogenetic tree) can all be linked to or cause microbiotamediated diseases, such as IBD. (C) Distinct Strains of the Same Bacterial Species can have Opposite
effects on Disease Susceptibility. The problem of strain variability within taxonomically ”identical” isolates is
highlighted using three simplified examples of Bacteroides fragilis strains. Note that the strains can be highly
(>90%) identical at the genomic level. Nonetheless, small differences in gene content can result in large
functional differences. On the left, expression of genes necessary for synthesis of polysaccharide A (PSA)
results in an immunoregulatory phenotype, while on the right side expression of a toxin results in an
inflammatory phenotype.
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Figure 2. Functional Profiling of the Microbiota. (A) IgA-Seq identifies immunologically-important members
of the gut microbiota. IgA-Seq combines bacterial cell sorting and 16s rRNA gene sequencing to identify
specific members of the microbiota that are coated with the secreted immunoglobulin IgA. Cells isolated
from fecal samples are stained with anti-IgA antibodies and sorted based on their IgA coating. The IgAcoated and uncoated fractions are then subjected to 16s rRNA gene sequencing to identify species that are
enriched for IgA coating. (B) Functional classification of the microbiota. Select methods for functional
classification of the microbiota, including representative ‘omics’-based approaches (metagenomics and
metabolomics), and targeted functional profiling (IgA-Seq) are depicted. Metagenomics identifies microbial
taxa and genes present in a microbial community, metabolomics identifies the various small-molecule
compounds produced by the microbial community, and IgA-Seq identifies particular microbes that interact
intimately with the mucosal immune system. Omics approaches and targeted functional profiling approaches
possess complementary strengths and weaknesses. Omics approaches are generally unbiased, highthroughput, and high-content, but depend entirely on prior annotations to assign functional activities; in
contrast, targeted functional profiling approaches can create new functional assignments to specific genes or
taxa, but are generally restricted to examining a single function at a time.
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Chapter 2: Selection and Pressure on the Microbiota

To identify the role of host-microbe interactions in shaping the microbiota, it is
necessary to understand the selective pressures acting on microbes and the alternative
mechanisms of overcoming or adapting to these pressures. The first portion sets the stage
by discussing the basic features of bacterial life as they relate to growth and death. Next,
the environmental challenges associated with life in the intestine are discussed, moving
from the tissue-specific feature of peristalsis to the competitive features present in any
population of mixed microbes. Finally, there is a brief discussion of the effects of the host
immune system on the microbiota, as a distinctive environmental factor shaping hostassociated microbial communities.

Growth and death
The mammalian intestine presents a wide range of physicochemical conditions that
bacteria can explore to find an optimal niche. These include longitudinal and transversal
variations in pH, exposure to oxygen or other gases, and host- or diet-derived molecules1.
In many cases, it is difficult to appropriately model these features in an in vitro system to
adequately measure even simple features such as bacterial growth and death rates. Even if
an adequate system is identified to study bacteria in one setting, there may be variability in
bacterial lifestyle in a different location or at a different time in the gut2. It therefore
remains a generally open question what the exact physiology of bacteria is in situ.
Nonetheless, a variety of quantitative assessments broadly suggest that bacterial
growth in the intestine or other human-associated environments is substantially slower than

39

optimal growth in in vitro systems. Methods including dye-tracing (which tracks number
of cell divisions)3, ribosomal hybridization (a readout of cell proliferation capacity)4,
colony counts5, inference from mutation rates, or calibration of metagenomic “peak-totrough ratios”6 often reflect slower growth in situ when compared to the fastest growth
rates achievable in monoculture conditions. In some cases, these measurements reflect the
combined growth and death rates of the bacteria, but even isolation of precise growth rates
alone still identifies a relatively slow growth rate in vivo, with doubling times of several
hours even for microbes such as E. coli which can grow an order-of-magnitude in liquid
culture. Rates following colonization of previously-germ free animals can reflect faster
growth rates7, but have not been rigorously compared to steady-state growth rates across a
range of microbial species.
Importantly, many of these measurements still leave the question of bacterial cell
cycles in situ unclear. It is not universally known whether in situ growth is best represented
in lag phase, early/mid/late logarithmic phase, stationary phase, or an alternative cell state
not well captured in a standard logistic growth model. In particular, many of these methods
may fail to capture “maintenance” or “survival” states of microbes, metabolic states that
have been identified in a wide range of environmental microbes8. In these states, energy
consumption orders of magnitude (up to 1000-fold) below that required for growth can
sustain regulation of osmolarity, pH, and macromolecular quality control mechanisms, in
the absence of DNA replication or biomass production necessary for cell division. Whether
such dormant populations exist in vivo is an open question. It is an intriguing possibility
that microbes in experimentally inaccessible niches (i.e. not readily sampled in feces), or
those undetectable by sequencing-based approaches but known to be present (such as
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opportunistic pathogens that show low-level carriage in healthy individuals before
blooming under some external stimulus), might exist in such a metabolic regime, and
therefore exhibit aspects of biology unlike any modeled in growth-enabling in vitro
systems.
The final question is how overall bacterial growth is built by the combination of
intrinsic growth and death rates. Multiple studies comparing colony counts, which measure
live cells, with total cell count measures have suggested that the vast majority of intestinalresident cells are alive (specifically, able to form colonies on appropriate media). This is
in agreement with growth models based on population dynamics of trackable engineered
strains, which suggested that steady-state growth is characterized by a slow death rate
relative to initial colonization dynamics9.

Peristalsis
The total bacterial population is also impacted heavily by elimination of cells,
regardless of their growth or metabolic status. In the intestine, a critical mediator of cell
removal or elimination is the longitudinal liquid flow, driven by host peristalsis. Precise
flow rates vary both temporally and longitudinally along the gastrointestinal tract10.
Estimates of flow rate based on fluid elimination suggest minimal average flow rate of 20
µm/s in the human colon11. This is comparable to the maximal chemotactic speeds
observed for a variety of gut microbes. Thus, in order to combat peristalsis purely by
motility, bacteria would need to dedicate a substantial portion of their energy to directed
migration “upstream”, and non-motile bacteria would be rapidly eliminated. Therefore, it
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seems unlikely that bacteria avoid elimination purely or even primarily through intrinsic
motility.
Theoretical and experimental modeling suggests that intestinal contractions create
sufficient mixing and “backflow” to maintain bacterial density10,11. This mixing may be
largely responsible for maintaining the overall bacterial population within the gut, in spite
of the low growth rates that would seem incompatible with dramatic removal pressures.
However, at the level of an individual microbial population, peristalsis still represents a
strong selective pressure. This is most well illustrated by detailed investigation of the
zebrafish microbiota, where the population may be readily imaged and monitored over
time. In that setting, it has been clearly demonstrated that populations more vulnerable to
physical removal – particularly bacterial aggregates that are subjected to different fluid
forces – are readily removed from the intestinal tract and show strong fitness defects
relative to comparably growing but more dispersed microbes12-15.
Another mechanism for avoiding the pressures applied by peristalsis is to reside in
sheltered niches of the gut. In particular, adhesion to host surfaces (mucus or directly to
epithelial cells) would theoretically enable microbes to avoid removal by peristalsis. While
an attractive hypothesis, it is unlikely that this accounts for the major source of bacterial
repopulation in the face of flow-based removal. Modeling suggests that even if the mucus
layer were fully colonized at the maximal achievable density, the bacterial population
resident there would be unable to replace those cells removed due to flow at maximal
achievable growth rates, let alone the slow observed in situ growth rates. However, for an
individual microbial species, adhesion may offer a sufficient “reservoir” for maintenance
of the population, based on the particular growth and death rates for that microbe. In
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particular, adhesion (or close host association) offers the potential for access to unique
host-derived signals or nutrients, and therefore the local growth rate may be different from
the bulk population growth rate16. It will be critical to quantitatively examine bacterial
population dynamics in situ to understand the relative contributions of mixing, motility,
luminal growth, and replenishment from host-associated subpopulations in maintenance of
bacterial cell numbers, although it is clear that most of these are individually insufficient
to maintain the global microbiota density in the gut.

Direct Competition
The above sections have focused on intrinsic properties of microbial lifestyles in a
dynamic environment, considered in isolation. However, the intestinal microbiota is
comprised of hundreds of strains that may compete for spatial or nutritional niches. As in
other complex microbial communities, a wide range of direct antagonistic mechanisms are
used by intestinal microbes to gain competitive advantages over other community
members. These include a range of contact-dependent mechanisms, as well as the
production of soluble anti-microbial effectors.
Dominant forms of contact-dependent microbial competition include contactdependent inhibition (CDI) systems and type 6 secretion systems (T6SS), both of which
are abundant among gram-negative bacteria17,18. Both deliver toxins to target cells through
a large surface-associated complex, although the mechanistic details differ. Examples of
competitive advantages for CDI- or T6SS-expressing strains over similar microbes in the
mammalian gut environment illustrate that the density, localization, and mixing of
microbial populations is sufficient to enable complete depletion of non-competitive
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strains19-21. Importantly, metagenomic analyses have also illustrated widespread carriage
of immunity proteins that protect against T6SS-delivered toxins even in the absence of
T6SS effectors, suggesting that potential intoxication is a sufficient danger to drive longterm maintenance of protective genes22. While contact-dependent inhibition systems have
been identified in gram-positive microbes, their presence and fitness advantages in the
microbiota have not been evaluated, but it is likely they may play similar roles in shaping
gram-positive microbial communities23.
Bacteria also produce a wide range of soluble anti-microbial molecules, especially
peptide derivatives and small proteinaceous toxins17. These include nonribosomal peptides
(NRPs) as well as ribosomally synthesized post-translationally modified peptides (RiPPs),
which include bacteriocins, lantibiotics, and microcins. Production of both NRPs and
RiPPs has been noted in the human microbiota, across a range of species, and evidence
exists for a competitive fitness advantage in antibiotic NRP/RiPP producers24-27. While
these are soluble molecules and can therefore act at a distance, it is important to consider
the physical limits on the reach of these molecules (see Appendix, below). The relatively
low inhibitory potential of these molecules (i.e. >>1 µM)26 prohibits their production in
inhibitory concentrations even in a static setting at distances much beyond ~1mm. Thus,
these small molecules still likely act microscopic regions to enable local competition in a.
defined spatial niche, rather than shaping global tissue microbial composition in a widereaching fashion unless produced across a wide area of the intestine.

Nutrient Acquisition and Metabolic Networks
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A critical determinant of microbial fitness in the intestine is the ability to acquire
and utilize specific nutrients. These may include simple or complex carbohydrates, amino
acids, steroids, lipids, metals, and a variety of other small molecules required as metabolic
precursors or cofactors28. The sources of these molecules may include host diet, hostderived molecules, and byproducts from other microbes. Tremendous variability exists in
preferences for metabolic substrates within and across phylogenetic groups, including the
ability to uptake and break down complex carbohydrates and polysaccharides as well as
the relative utilization efficiencies of simple sugars for energy production. Nonetheless, it
is clear that in a wide range of cases, expansion of metabolic niches is one of the strongest
competitive advantages available to microbes in the gut.
Extensive work on polysaccharide utilization loci (PULs) in Bacteroides species
and strains has provided a useful example of the advantages provided by an expanded
metabolic niche29. Strains may harbor dozens of PULs, often comprising homologs of the
outer membrane starch binding protein and transporter SusC/D along with hydrolases that
break down the polysaccharide either extracellularly or after uptake. A variety of genetic,
biochemical, and structural studies have illustrated how PULs may discriminate between
sugars and enable growth in a variety of nutrient conditions30-36. In particular, acquisition
of PULs that enable unique utilization of a polysaccharide can provide dramatic advantages
in vivo, most notably illustrated by the example of a porphyran utilization locus37.
Controlled administration of dietary porphyrin, in the form of seaweed, enabled rapid and
substantial growth, up to 10,000-fold in a single day. Notably, this is comparable to the
measured in vitro growth rate on porphyran as a sole carbon source, with a doubling time
of ~100 minutes, and enables growth to extremely high densities approaching 1011 cells/mL
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(the approximate density of the total intestinal microbiota). This suggests that a major
limiting factor in bacterial growth in vivo is nutrient availability, and relief from that
pressure by removal of diet-imposed limits or metabolic competition enables near-maximal
growth potential. Similarly, removal of a preferred nutrient substrate can result in rapid and
near-complete elimination of bacterial strains from the gut. Observations of the clear fitness
advantages imparted by individual metabolites have also been shown for nucleotides and
metal-containing vitamins in gut Bacteriodes strains38-40. Numerous studies have also
illustrated the ability for host-derived molecules to support individual microbes during
homeostasis or periods of inflammation41-43, reinforcing that nutrient availability,
regardless of source, is a key determining factor for microbial growth.
These studies have illustrated the critical role of nutrient acquisition in bacterial
fitness in the gut. In a complex environment colonized by many species of microbes, as in
the gut, competition between microbes for common substrates and cooperation through
sharing of metabolic byproducts both enable growth patterns that do not necessarily reflect
fitness or growth capabilities in isolation. Metabolic exchange in complex microbial
communities has been measured in simplified experimental systems44 and modeled through
computational methods such as flux balance analysis (FBA), which uses genome-scale
metabolic reconstructions to balance input and output through multiple metabolic pathways
from a variety of microbial community members45. Importantly, modeling and
experimental investigations have suggested that metabolic exchange may only be stable if
there are sub-optimal growth rates for many community members46,47. This is a critical
observation in line with the observed slow growth rates in situ (discussed above) and the
overall stability of the microbiota. Taken all together, the most plausible in vivo scenario
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for the microbiota under homeostatic conditions is an environment in which most nutrients
are limiting for most species, metabolic competition between closely related microbes
enforces metabolic niches, and extensive metabolic exchange supports and stabilizes the
complex community. This has been recently supported by the demonstration that
ecologically connected communities assemble in a predictable manner and order, related
to co-dependent interactions between microbes, during neonatal colonization, and that
host-derived nutrients support community assembly.

The Host Immune System
A unique environmental challenge of tissue colonization is the direct action of the
host immune system and its ability to exert untargeted or targeted effects on the resident
microbial community. In the intestine, a dominant mechanism of immune targeting is the
production of large quantities of IgA, the most highly produced antibody isotype in the
body48. IgA can be produced through T-dependent and T-independent pathways. While Tindependent IgA, often targeting polymeric structures such as lipid or glycan components
of cell membrane and cell walls, can coat a wide range of microbial species, the dominant
source of specific IgA coating of highly targeted strains appears to be T-dependent. Tdependent IgA production, accompanied by extensive somatic hypermutation that can
increase affinity, specificity, or cross-reactivity, enables selective shaping of the microbiota
by the host immune system. Interestingly, antibody binding can shape the microbiota
through both positive and negative effects on the targeted microbes. For example,
“enchaining” that causes targeted bacteria to clump together leads to increased removal by
peristalsis (as discussed above)49, while IgA binding can also provide beneficial nutrients
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to microbes to support their growth50,51. The importance of IgA is reinforced by multiple
mechanisms evolved within the microbiota for binding, cleaving, or inducing IgA
production by the host52-54.
IgA is a major player in immune-microbiota interactions, due to its secreted nature,
high concentration, and breadth of targeting capabilities. Several grams of IgA are secreted
into the gut each day, sufficient for more than a thousand-fold excess of IgA molecules to
bacterial cells in the gut. Numerous other secreted antimicrobial proteins and peptides can
also shape the microbiota, and the evidence of their selective pressure can also be shown
through adaptation of gut resident microbes to avoid targeting through modification of
targeted structures such as cell membrane composition55.
While IgA and other secreted molecules are well appreciated as potential immune
mechanisms to shape the microbiota, there is clear but perhaps underappreciated potential
for interaction with host immune cells. For example, luminal neutrophil infiltration is a
common feature of inflammatory gut conditions, although fecal leukocytes can be detected
even at baseline56-58. Intriguingly, human neutrophils express the receptor for IgA (FcaR1)
and might therefore respond to coated microbes in the lumen, while mice lack an IgA
receptor completely. Studies in mice may therefore neglect the ability of luminal
neutrophils to act in a directed manner, guided by IgA coating. Myeloid cells can directly
sample the contents of the lumen through protrusions that extend between epithelial cells5961

, and intraepithelial lymphocytes reside in extremely close proximity to microbes62,63.

The extent to which these cell types may also migrate across the epithelium and exert
luminal actions remains unclear, but it is highly plausible that during conditions of
intestinal inflammation, when barrier integrity may be diminished, or even at baseline
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during rapid epithelial turnover, some of these cells may reach the lumen and respond
directly to microbes there.

Summary
Overall, the intestinal microbiota exists in a dynamic, challenging environment,
where a variety of selective pressures drive microbial physiology and evolution. These
include peristaltic flow, irregular nutrient availability and competition for metabolically
essential molecules, direct antagonism from other microbes, and the directed and generic
effects of the host immune system. Individual experiments have illustrated that any of these
individually may be sufficient to mediate complete elimination of particular microbes, but
their relative roles in shaping the global microbiome remain unclear. Importantly, direct
interactions with host-produced molecules may provide microbes with avenues to mitigate
all these pressures – whether by anchoring to host cells or structures to avoid flow-mediated
expulsion, or cleavage / evasion of immune molecules.
Appendix: Quantitative Estimations of Small Molecule Production in the Microbiota
Numerous aspects of bacterial activity in the gut are controlled by soluble small
molecules, ranging from genuine small molecule metabolites (e.g. SCFAs, glucose) to
small proteins such as bacteriocins. This appendix will briefly treat on the quantitative
estimation of production and biodistribution of these molecules, using simple order-ofmagnitude calculations to provide a framework for boundaries on the potential roles of
these molecules. Quantitative estimates are primarily derived from the Bionumbers
database, with references provided for special values (Table 2.1). Broadly, these
estimations suggest that microbially-derived small molecules must either a) act over small
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distances, b) exhibit high potency, or c) be produced at scales comparable to central
metabolic mediators. Thus, wide-reaching modestly potent molecules are likely
fundamental metabolic byproducts.
The first analysis will focus on the production of small molecules. A suitable
benchmark may be the production of ATP. Two independent analyses suggest that ATP
production in E. coli occurs at a rate of approximately 107 molecules/cell/second – that is,
each cell produces approximately 10 million ATP molecules per second. First, a value of
~12 * 109 molecules of ATP is required to produce 1 cell. At a doubling time of 20 minutes
(1200 seconds) for fast in vitro growth, this requires a production of 107 molecules/second.
An alternative measure is the pre-cell production rate during growth on acetate –
normalizing the production of 855 mmol/min/L to a cell volume of ~1.4 fL gives a value
of approximately 107 molecules/cell/second. Thus, a useful benchmark to remember is that
production of ATP can be reasonably estimated at 107 molecules/cell/second. This may
serve as a useful upper limit for estimates of small molecule production, as this reflects the
production of the major energetic currency of a cell under conditions of robust growth. It
is unlikely that any molecule is likely to be produced substantially faster or in substantially
higher levels.
A useful check that this may reflect small molecule production capacity in the
microbiota is given by measurements of acetate production, which suggest a rate of
approximately 1018 molecules produced per second by the collective microbiota – requiring
production of only 104 molecules/cell if all microbes are actively producing acetate, and
only reaching the ATP estimation rate of 107/cell/s if 0.1% of microbial cells produce
acetate. As a critical metabolic byproduct of fermentation metabolism by a range of

50

microbes, we see that this matches the upper limit imposed by ATP production and
suggests that even metabolically critical molecules may be produced substantially below
this rate. This is also consistent with observed average kcat enzymatic rates and protein
abundances,

which

together

suggest

an

average

production

rate

of

~105

molecules/cell/second for central carbohydrate metabolism. It is important to note that even
alternative metabolic enzymes, such as those involved in intermediate metabolism, can be
more than 10 times slower than central carbohydrate metabolism and expressed at lower
levels. It has been additionally shown, at least for E. coli metabolic enzymes, that maximal
in vivo apparent rates are comparable with in vitro calculated catalytic rates, suggesting
these estimates are generally useful as maximal rates for cellular production.
How does production of non-metabolic small molecules of interest compare? These
enzymes can be dramatically slower and expressed at substantially lower levels. For
example, the production of erythromycin depends on the polyketide synthase DEBS, which
has a kcat over 1000-fold slower than average central metabolic enzymes. At modest levels
of protein expression, at the low end of metabolic enzyme levels, production may be
limited to 10-100 molecules/cell/second. This illustrates that even important and bioactive
molecules may be produced at what appear to be very slow rates on a per-cell basis.
Do these values explain systemically relevant production by a limited number of
microbes? Given per-cell production rates, it is straightforward to estimate the maximum
achievable tissue concentrations of small molecules as a function of bacterial abundance.
Figure 2.1 is a graph illustrating the maximal colonic concentrations achievable by
microbes producing molecules according to a variety of the described rates. At the top,
shaded in grey, are concentrations that would require rates of production greater than the
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theoretical maximum of 107 molecules/cell/second. The blue range represents metabolic
byproducts, showing central carbohydrate metabolic byproducts at the upper end and
secondary metabolites at the lower end. At the lowest range, along the red line, is
production at rates comparable to the slow estimated production rate of erythromycin.
These estimates illustrate that high bioactive concentrations above 1 mM are readily
achievable, but only for highly abundant microbes or small molecules produced at rates
matching that of core metabolic programs (see the illustrated point, showing production of
a secondary metabolite by a bacterium making up 10% of colonic bacteria). Specialized
small molecules produced by lower abundance bacteria reach only modest concentrations
in the colon (the second point, showing production at an erythromycin-like rate by a
bacterium at 1% abundance). It is worth noting that, given perfect uptake, serum
concentrations would reach 30-50% the indicated levels from the colon, owing to the
volume differential, while small intestinal concentrations are likely to be ~1000-fold lower
for an analogously producing population present there, given similar total tissue volume
but greatly reduced bacterial population size.
It is important to note that these are estimated maximum concentrations, based on
a number of simplifying assumptions. The concentrations plotted are the maximal
concentrations assuming once daily turnover of intestinal contents – time-averaged
concentrations are therefore likely to be lower. Additionally, these concentrations neglect
the requirement for export from the bacterial cell. While the export pathways for many
small molecules are unknown, it is useful to note that the maximal uptake rate of glucose
in E. coli is ~106 molecules/cell/second, which might serve as an estimate for maximally
efficient transport – therefore limiting accumulation of the most abundant metabolites.

52

Precursors for metabolite synthesis may be unavailable under certain conditions based on
host dietary intake or competition with other microbes, reducing the output rates even for
the fastest metabolic enzymes. Diffusion limits the potential spread of small molecule
metabolites, as diffusion times to cross distances greater than ~100 µm are slower than
intestinal flow rates, preventing diffusion “upstream”, and distances greater than ~1 cm
require diffusion times on the order of 1 day or longer, preventing macroscopic spread of
a locally produced metabolite. This means that, in the absence of intestinal contractions
that promote mixing (which may indeed serve to partially mitigate these effects), for a
bacterial population in the center of the lumen of the large intestine, with a diameter of
several cm, the concentration of small molecules that may reach the host is essentially
negligible, even under the highest rates of production – while the concentration near those
producers in the center of the lumen may be extremely high.
While only crude estimates, these numbers illustrate the range of feasible
production of bioactive small molecules by members of the intestinal microbiota. They
align with observed capabilities of intestinal microbes, such as the production of high
micromolar concentrations of serum IPA or TMAO derived from fundamental metabolic
pathways of Clostridium species in a cell-concentration dependent fashion. Local
concentrations may certainly reach above these estimates (concentrations in the
flow/diffusion-limited local area of ~100 µm, or several dozen cell lengths, may be up to
109 times higher than overall intestinal concentrations), and indeed suggest that the
potential for microbes to influence their immediate microenvironment is readily achievable
even with relatively slow production rates - explaining the potential evolutionary
conundrum that even critical molecules may be produced at very low per-cell rates.
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Property

Bionumbers ID / reference

Value

ATP production rate on acetate

105260

855 mmole/min/liter

ATP requirement for growth

101981

1.21 *10^10

Bacterial cells in human colon

112982

10^14

Bacterial cells in human small intestine

105711

10^8 / mL

Concentration of IPA in serum

PMID 29168502

~10 µM

Concentration of TMAO in serum

PMID 31831639

~10 µM

DEBS kcat

PMID 8652546

0.05 /s

Diffusion constant of glucose

104089

0.6 * 105 µm2/s

Dry weight of E. coli cell

103904

280 fg

Glucose uptake rate of E. coli

109376

12.83 g/g CDW/h

Kcat of metabolic enzymes

111415

<100 /s

Length of E. coli cell

100001

~2 µm

Protein copy number per cell

110443

max. ~10^5

Rate of acetate production

PMID 26516911

100 mmol / 12 hours

Size of small intestine

111127

1.5 L

Time required for diffusion of 0.1 mm

115474

5 seconds

Total blood volume of human

101707

5.5 L

Volume of E. coli cell

114924

1.46 fL

Volume of human large intestine

111759

~2 L

Volume of human small intestine

111127

~1 L

Table 2.1: Bionumber and PMID references for values used in calculations in this
Appendix.
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Figure 2.1. Graphical depiction of theoretical colonic concentrations of bacterial
metabolites as a function of bacterial abundance.
The grey shaded area depicts theoretically unattainable concentrations. The blue shaded
area represents metabolic byproducts, bounded by the theoretical production rates of
central and secondary metabolites at the top and bottom, respectively. The red line depicts
non-metabolic small molecules, based on the estimated production rate of erythromycin.
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Abstract
Autoantibodies that recognize extracellular protein epitopes (the “exoproteome”) exert
potent functional effects that underlie numerous disease processes. Identifying these
antibodies can thus provide insights into the pathophysiology of a wide spectrum of
illnesses and therapeutic strategies to treat them. Here, we developed Rapid Extracellular
Antigen Profiling (REAP) as a technique for comprehensive and high-throughput
discovery of exoproteome-targeting autoantibodies. With REAP, patient samples are
applied to a genetically-barcoded library containing 2,688 unique members of the human
exoproteome displayed on the surface of yeast. Antibody-coated cells are isolated by
magnetic selection and deep sequencing of their barcodes is used to identify the displayed
antigens, thereby converting an antibody:antigen binding event into a digital sequencing
readout. To benchmark the performance of REAP, we screened 77 patients with the rare
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monogenic autoimmune disease autoimmune polyendocrinopathy-candidiasis-ectodermal
dystrophy (APECED). REAP sensitively and specifically detected known autoantibody
reactivities in APECED, including responses against type I interferons, IL-17, IL-22, and
gastric intrinsic factor. REAP also identified highly prevalent reactivities that had not been
previously described such as those against the glycoprotein hormone GPHB5. We
additionally screened 106 patients with systemic lupus erythematosus (SLE) and identified
novel autoantibody reactivities against a diverse set of antigens including growth factors,
extracellular matrix components, cytokines, and immunomodulatory proteins. Several of
these responses were associated with disease severity and specific clinical manifestations
of SLE, including autoantibodies that target immunoreceptors, antagonize the proinflammatory cytokine IL-33, and recognize endosialin (CD248) and the chemokine
CCL8. In summary, these findings demonstrate the utility of REAP to atlas the expansive
landscape of exoproteome-targeting autoantibodies in patients.

Introduction
Autoantibodies play a major etiological role across a wide range of diseases spanning
autoimmunity, cancer, metabolic dysfunction, cardiovascular disease, infectious diseases,
and even neurological and neurodegenerative conditions1–8. Though autoantibodies are
commonly associated with adverse effects, they can also exhibit disease-ameliorating
functions that are beneficial to patients. For example, immunosuppressive anti-cytokine
autoantibodies are associated with less severe disease in numerous autoimmune
conditions9,10; similarly, anti-tumor specific and opsonizing antibodies are associated with
better survival in cancer patients11–13. Thus, analogous to genetic mutations, autoantibodies
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may explain a significant fraction of the clinical and phenotypic variation seen between
individuals. Discovery of novel functional autoantibody responses in patients therefore has
the potential to uncover key etiologic factors and therapeutic targets similar to the study of
human genetics.

Within the human proteome, a particularly important group of autoantibody targets are
extracellular and secreted proteins (collectively, the “exoproteome”). Because antibodies
are themselves large (150 kDa) secreted proteins, they are most likely to recognize and act
upon targets that reside within the same extracellular compartment14. While state-of-theart technologies such as protein/peptide microarrays, proteome-scanning libraries using
phage (PhIP-seq) and bacterial display have enabled the discovery of novel autoantibodies
in a variety of diseases15–23, these systems have limited sensitivity to detect autoantibodies
against extracellular targets. This is due in part to the inherent difficulty of working with
extracellular proteins, which often have unique folding requirements that include signal
peptide removal, disulfide bond formation, and post-translational modifications such as
glycosylation. Many of these features are not captured by platforms that express proteins
or peptides in prokaryotic systems. Similarly, technologies that rely on the use of peptide
fragments are not able to detect autoantibodies that recognize “conformational” protein
epitopes (i.e., three dimensional epitopes present when a protein is folded into its native
state). This limitation may significantly hamper autoantibody detection, since as many as
90% of antibodies recognize conformational epitopes as opposed to linear peptides24.

Here, we describe Rapid Exoproteome Antigen Profiling (REAP), a new method to
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discover functional antibodies against the exoproteome. REAP leverages yeast-display
technology to assess the presence of autoantibody responses to 2,688 extracellular proteins
present in patient serum or plasma samples through a next-generation sequencing-based
approach. We use REAP to screen a cohort of 77 APECED patients and successfully
identify known autoantibodies along with novel “public” (present in many patients) and
“private” (present in only a few patients) reactivities. We further apply REAP to a cohort
of 106 patients with SLE and identify autoantibodies targeting cytokines, cytokine
receptors, growth factors, extracellular matrix components, and immunomodulatory cell
surface proteins, and validate several of these reactivities through orthogonal assays. In
both SLE and APECED, we identify autoantibody responses that are associated with
disease severity and specific clinical disease manifestations. Finally, we find that
autoantibodies in SLE patients that target the co-inhibitory ligand PD-L2 and the cytokine
IL-33 have functional antagonist activity ex vivo. These results indicate that REAP is
broadly useful for the discovery of autoantibodies targeting the exoproteome and that
functional autoantibodies within patient populations may provide key insights into disease
pathogenesis and therapeutic approaches.

Results
Development of Rapid Exoproteome Antigen Profiling
To develop a system capable of detecting autoantibody responses against conformational
extracellular proteins, we elected to use yeast surface display to comprehensively sample
the human exoproteome. As eukaryotic cells, yeast contain several features that enable
them to express extracellular proteins, including endoplasmic reticulum chaperones,
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glycosylation machinery, and disulfide bond proofreading systems25. Accordingly, a
diverse range of mammalian extracellular protein families have been successfully
expressed with yeast display, including proteins with folds such as the immunoglobulin
superfamily (IgSF), TNF superfamily (TNFSF), TNF receptor superfamily (TNFRSF), von
Willebrand factor A (vWFA) domains, fibronectin domain, leucine-rich repeat (LRR),
EGF-like, insulin-like, cytokines, growth factors, and even complicated assemblies like
peptide:MHC complexes, T cell receptors, and intact antibodies26–41. We therefore
constructed a genetically-barcoded yeast-displayed exoproteome library of approximately
2,700 human extracellular and secreted proteins. The library comprises actively displayed
proteins from a wide range of protein families and encompasses 87% of all human
exoproteins with extracellular regions from 50-600 amino acids in length (Fig. 3.1a,
Supplementary Fig. 3.1a-c). While there is within-library heterogeneity in individual
protein abundance and the number of unique barcodes associated with each gene, the
library is relatively uniform and the vast majority of proteins fall within a narrow range
suited to coverage by standard next-generation sequencing approaches (Fig. 3.1b,c). Full
details on the design and composition of the library are described in the Methods and in
Supplemental Table 1.

We next optimized procedures for high-throughput identification of seroreactivities against
proteins in our exoproteome library for REAP (Fig. 3.1d). Briefly, IgG purified from
patient serum or plasma is incubated with the yeast library. Autoantibody-coated cells are
then isolated by magnetic separation and deep sequencing of the library-encoded DNA
barcodes is used to identify the corresponding antigens encoded by these cells. To quantify
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the degree of antibody reactivity to a given antigen, we developed a custom scoring
algorithm (“REAP Score”) based on the enrichment of each antigen’s barcodes after
selection (see Methods). Screening of the exoproteome library with a set of nine
conformation-specific monoclonal antibodies against a variety of extracellular proteins
showed that all antibody targets were detected specifically and robustly (Fig. 3.1e,f). To
further assess the conformational nature of proteins displayed in the library, we performed
a REAP screen using a panel of 30 recombinant proteins with known binding partners in
the library. REAP accurately detected the cognate binding partners for each of these
proteins, with minimal enrichment of off-target proteins (Fig. 3.1g).

Evaluation of REAP performance in APECED
To evaluate the capacity of REAP to detect exoproteome-directed autoantibodies in
complex patient samples such as polyclonal responses in serum, we screened a cohort of
77 APECED patients (Supplementary Table 2). APECED, also known as autoimmune
polyglandular syndrome type-1 (APS-1), is a rare genetic autoimmune disease caused by
mutations in the autoimmune regulator (AIRE) gene, resulting in loss of central tolerance
and the development of chronic mucocutaneous candidiasis (CMC), severe
endocrinopathies and other nonendocrine autoimmune sequelae such as pneumonitis,
hepatitis, alopecia, vitiligo, and vitamin B12 deficiency/pernicious anemia42. Interestingly,
APECED patients harbor widespread and pathognomonic autoantibodies targeting
numerous cytokines including type I and type III interferons, IL-22, IL-17A, and IL-17F43–
47

. REAP readily identified autoantibody responses against these cytokines in APECED

patient samples, but not in samples from healthy controls (Fig. 3.2a). Furthermore, the
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frequencies of these autoreactivities in APECED patients closely matched the frequencies
determined from previous reports using gold-standard methodologies such as enzymelinked immunosorbent assay (ELISA) and luciferase immunoprecipitation system
immunoassay (LIPS) (Fig. 3.2b)18,43,47. We also identified autoantibodies against gastric
intrinsic factor (GIF), lipocalin-1 (LCN1), IL-5, IL-6, protein disulfide-isomerase-like
protein of the testis (PDILT), and BPI fold containing family member 1 and 2 (BPIFA1/2),
which have been previously described in APECED18–21,48. With respect to GIF reactivities,
the results seen with REAP demonstrated strong concordance with anti-GIF ELISA results
from the same patients (Fig. 3.2c).

To investigate the reproducibility of REAP, we compared log2[fold enrichment] between
technical (intra-assay) replicates across all APECED patient samples and found strong
positive correlations between replicates (median R2 = 0.914; Supplementary Fig. 1d). To
investigate the sensitivity of REAP, we titrated varying amounts of IgG and performed
REAP and ELISA side-by-side for four autoantigens (Supplementary Fig. 1e,f). In each
case, REAP exhibited higher sensitivity than ELISA by 1-2 orders of magnitude, as seen
by the calculated EC50 values (Fig. 3.2d). Taken in aggregate, these data indicate that
REAP is capable of detecting known autoantibody responses against extracellular proteins
with high sensitivity and precision.

APECED patients exhibit broad exoproteome-targeting autoantibody reactivities
Previous reports using protein microarrays and PhIP-seq have shown that APECED
patients have greatly elevated numbers of autoantibody reactivities at a proteome-scale
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compared to healthy controls. Analyzing the REAP data, we found that global
autoreactivity present in APECED also extends to the exoproteome (Fig. 3.2e,
Supplementary Fig. 2a). While some of the reactivities we observed have been previously
characterized, the screen also uncovered numerous previously undescribed “public”
(present in more than one patient) and “private” (present in only one patient) reactivities.
Two notable public reactivities were those against glycoprotein hormone beta-5 (GPHB5),
a thyrostimulin subunit, and pancreatic triacylglycerol lipase (PNLIP), a tissue-restricted
antigen that is regulated by Aire in the thymus49. Using ELISA, we confirmed the presence
of autoantibody responses against these proteins and found that the titers of autoantibodies
were high, ranging from EC50s of approximately 1:100 to 1:10,000 (Fig. 3.2f,g). We
additionally were able to correlate particular serological responses to specific, variable
clinical features of APECED. For example, we found that autoantibodies against lipocalin1 (LCN1) and BPIFA1, which had previously been identified in APECED patients with
Sjogren’s-like syndrome48, were enriched in a subset of APECED patients with
pneumonitis (6 out of 28 with pneumonitis), a life-threatening non-endocrine complication
of APECED, but universally negative in 49 patients without pneumonitis or healthy
controls (Fig. 3.2h). Of note, BPIFA1 reactivity was detected in a patient with biopsyproven pneumonitis without reactivity to the known lung-targeted autoantibodies KCNRG
and BPIFB1, which have an overall sensitivity of ~75% but are negative in a quarter of
patients with biopsy-proven pneumonitis50. Interestingly, the single patient in our cohort
with exocrine pancreatic insufficiency, a rare manifestation of APECED42, uniquely
harbored reactivity to colipase (CLPS), an essential cofactor for pancreatic lipase and
related lipases (Fig. 3.2a)51. Thus, REAP enabled the detection of novel autoantibody
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reactivities in the monogenic disease APECED, as well as correlations of autoantibodies
with clinical features of the disease.

REAP identifies previously undescribed autoantibody reactivities in SLE patients
We sought to apply REAP to study SLE, a systemic polygenic autoimmune disease
characterized by loss of tolerance to nucleic acids52. Though autoantibodies are a defining
feature in SLE, particularly those against nucleic acids and nuclear protein complexes53,
the role of functional autoantibodies that target the exoproteome is less well established.
We thus performed REAP analysis on samples from a cohort of 106 SLE patients and 20
healthy controls. Patient and control demographics are shown in Supplementary Table 3.
Compared to APECED, we found that exoproteome-targeting autoantibodies in SLE
patients were strikingly heterogeneous; though a wide variety of autoantigens were
identified, there were essentially no public autoantigens and most reactivities were present
in only a few patients (Fig. 3.3a). Several reactivities identified by REAP included
autoantigens that have previously been described in SLE such as IL-6, type I interferons,
IL-1α, and TNFα (including identification of a therapeutic anti-TNF antibody administered
to one of the patients). We further identified numerous novel autoantibodies targeting other
cytokines (e.g., IL-4, IL-33), chemokines (e.g., CXCL3, CCL8), growth factors (e.g.,
VEGF-B, FGF-21), extracellular matrix components (e.g., epiphycan, vitrin), and
immunoregulatory cell surface proteins (e.g., FAS, PD-L2, B7-H4).

To validate the large number of candidate autoantibody reactivities identified by REAP,
we tested autoantibody reactivities against several different proteins using LIPS and ELISA
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and subsequently confirmed 16 of these autoantigens (Table 1, Fig. 3.3f,i, Supplementary
Fig. 3a-h, j, n-r). The subset of confirmed autoantibody reactivities consisted of both
shared and private reactivities and included examples of potentially pathological and well
as immunomodulatory reactivities, such as those against the extracellular matrix
component epiphycan (Supplementary Fig. 3n), the cytokine receptor IL-18Rβ
(Supplementary Fig. 3p), the death receptor FAS/TNFRSF6 (Supplementary Fig. 3e),
the co-inhibitory ligand PD-L2 (Fig. 3.3f), and the IL-1 family cytokine IL-33 (Fig. 3.3i).
We additionally characterized the titers and IgG isotypes for several of these responses,
finding that they spanned a wide range of titers (1:10 to >1:10,000) and isotype classes
(Supplementary Fig. 3n-r, t-v). Using these results, as well as orthogonal validations of
known APECED reactivities (Supplementary Fig. 3i-m), we performed receiver
operating characteristic (ROC) analysis to quantify the performance of the REAP scoring
algorithm. We found that REAP score sensitively and specifically predicted autoantibody
reactivity by ELISA and/or LIPS, with an area under the curve (AUC) of 0.892
(Supplementary Fig. 3s). Because REAP exhibits greater sensitivity for some antigens
than the ELISA/LIPS “gold standards” (as was the case for type I IFN autoantibodies in
APECED), this number may represent a conservative estimate of the true performance of
REAP in predicting autoantibody reactivity.

Exoproteome-targeting autoantibodies in SLE are functional and correlate with
disease severity
Given the broad distribution of autoantibody responses in SLE, we wondered if particular
responses or patterns of reactivity were associated with specific clinical features of the
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disease. At a global level, we found that the total numbers of autoantibody reactivities
identified with REAP correlated with worse clinical severity, as measured by the Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI) score54. In particular, we found
that samples from patients with severe disease (SLEDAI score ≥ 9) had significantly
increased numbers of autoantibodies compared to healthy controls (Fig. 3.3b,
Supplementary Fig. 2b). Furthermore, SLE patients in all severity groups had reactivities
that were not observed in healthy individuals and these patterns of reactivity were
associated with particular SLE disease phenotypes. For instance, we found that
autoantibody reactivities against the chemokine CCL8, the cytokine IFN-alpha-6, and the
C-type lectin CD248 (endosialin) were significantly associated with hematuria and that
VEGF-B reactivities were associated with leukopenia (Fig. 3.3c). Additionally, patients
positive for CCL8 reactivity had significantly higher SLEDAI scores, indicating more
severe disease (Fig. 3.3d). By contrast, patients who exhibited autoreactivity against a set
of immunoregulatory proteins (PD-L2, RAET1E, CD44, B7H4, BTNL8, CD300E, IER3,
TNFRSF6, CD300LG, LILRB2, IGLL1, and LILRB4) had significantly lower SLEDAI
scores compared to patients negative for these autoantibodies (Fig. 3.3e).

Finally, we characterized the functionality of autoantibodies against two novel
autoantigens identified by REAP, PD-L2 and IL-33. As the primary biological function of
PD-L2 is mediated by its binding to its receptor PD-1, we tested whether autoantibodies
against PD-L2 could block this interaction. Serum samples from an SLE patient with antiPD-L2 autoantibodies were present at titers >1:100 and inhibited the interaction between
PD-L2 and PD-1 in a dose-dependent manner, while serum from a control patient without
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anti-PD-L2 autoantibodies did not (Fig. 3.3f-h). To test the functional effects of anti-IL33 autoantibodies, we used the HEK-Blue IL-33 reporter cell line, which produces secreted
alkaline phosphatase downstream of an NFκB promoter that is activated by the IL-33
pathway. Bulk IgG (isolated via protein G) from the SLE patient harboring anti-IL-33
autoantibodies potently neutralized IL-33 signaling with an IC50 less than 0.01 mg/mL,
while IgG from a control patient without anti-IL-33 autoantibodies had no neutralizing
effect (Fig. 3.3i-k). These findings underscore the ability of REAP to discover novel
autoantibodies with functional biological effects.

Discussion
In the present study we show that REAP is a sensitive and high-throughput platform for
discovery of exoproteome-directed autoantibodies. By querying antigens in a
conformationally-active state, REAP enables identification of autoantibodies that are
difficult to detect, if not entirely invisible to other technologies. This was particularly
evident in our screen of APECED samples, as we found that REAP was considerably more
accurate in detecting a well-defined subset of known extracellular autoantigen reactivities
compared to protein arrays and phage-peptide display approaches. Furthermore, REAP
enabled the identification of numerous previously undescribed autoantigens in APECED
patients, a surprising finding given how extensively autoantibodies have been studied in
this patient population.

We also identified a large set of previously undescribed autoantibody reactivities against
the exoproteome in SLE patients, a considerably more heterogeneous population than
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APECED. The vast majority of these novel autoreactivities were relatively private with a
prevalence of <5% and in some cases present in only a single patient. Though these
autoantibody responses are rare, our studies suggest that they can exert large biological
effects that could meaningfully impact disease progression, akin to the effect of rare genetic
variants. For example, we identified a single SLE patient with very mild disease (SLEDAI
score of 1) who had extraordinarily high-titer autoantibodies against IL-33 that potently
neutralized IL-33 signaling in vitro. This suggests that these IL-33 antibodies may have
played a protective role that ameliorated the severity of the disease in this individual and,
by extension, that IL-33 blockade could represent a potential therapeutic strategy in SLE.
Indeed, circulating IL-33 concentrations are elevated in SLE patients and are positively
correlated with C-reactive protein concentrations and clinical manifestations such as
thrombocytopenia and erythrocytopenia55,56. Similarly, preclinical studies in mouse models
have demonstrated that IL-33 exposure is associated with autoantibody production and that
neutralization of IL-33 suppresses lupus-like disease57,58. Beyond IL-33, we also found that
SLE patients with autoreactivity against a set of immunoreceptors had substantially lower
disease severity, indicating that disruption of those pathways and/or opsonization of cells
that express the receptors could similarly exert a protective effect. Future investigation is
warranted to determine the prevalence of these autoantibodies in SLE patients and their
potential protective effects on a larger, confirmatory cohort. Nevertheless, our finding that
functional autoantibodies responses are highly variable between patients underscores the
need for technologies like REAP that can provide comprehensive, unbiased antibody
profiling for large numbers of patients. Without sufficient sample throughput and
representation of the exoproteome, these rare, but impactful autoantibody responses might
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not be readily detected.

REAP does have important limitations. While our data indicate that most exoproteome
antigens are displayed on the surface of yeast and we additionally demonstrated that dozens
of the library members are biochemically active (via recapitulating known binding
interactions), not all members of the exoproteome can be expressed in the yeast system.
This may be due to lack of specific chaperones, expression partners, or post-translational
modifications required for protein folding and activity. Furthermore, while yeast do
perform O- and N- linked glycosylation, their glycosylation patterns are characterized by
a hypermannose structure that is highly divergent from glycosylation seen in humans59.
Thus, autoantibodies recognizing specific glycoforms of their antigens would not be
detected with REAP. Further improvement in the REAP platform could therefore involve
yeast strain engineering to co-express mammalian chaperone proteins to enhance folding
of human antigens and glycosylation enzymes to produce more human-like glycosylation
patterns, as has been described for the yeast species Pichia pastoris60.

Though we initially applied REAP to the study of autoimmune conditions, an intriguing
avenue of future study with REAP and other serological profiling technologies is to
characterize autoantibody responses in diseases such as cancer, infectious diseases, and
neurological conditions that are not considered to have a primarily autoimmune etiology.
Identification of disease-modifying antibody responses in such conditions could implicate
new molecular pathways that contribute to disease pathology as well as novel therapeutic
targets and molecular diagnostics. Furthermore, patient autoantibodies could represent
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potential therapeutic agents themselves. Technologies such as REAP can enable these
discoveries by revealing the diverse landscape of functional autoantibody responses that
influence health and disease.

Materials and Methods
Library production.
Library design. An initial library of 3093 human extracellular proteins was assembled
based on protein domains, immunological functions, and yeast-display compatibility. The
extracellular portion of each protein was identified by manual inspection of topological
domains annotated in the SwissProt database (January 2018). For proteins with uncertain
topology, full sequences were run through SignalP 4, Topcons, and GPIPred to identify
most likely topologies. For proteins with multiple extracellular portions, in general the
longest individual region was chosen for initial amplification. cDNAs for chosen proteins
were purchased from GE Dharmacon or DNASU. The protein sequences were further
modified to match isoforms available in purchased cDNAs. An inventory of antigens
included in the library are compiled in supplementary table 1 (available at
https://www.biorxiv.org/content/10.1101/2021.02.11.430703v1.supplementary-material).

Library construction. A two-step PCR process was used to amplify cDNAs for cloning into
a barcoded yeast-display vector. cDNAs were amplified with gene-specific primers, with
the forward primer containing a 5’ sequence (CTGTTATTGCTAGCGTTTTAGCA) and
the reverse primer containing a 5’ sequence (GCCACCAGAAGCGGCCGC) for template
addition in the second step of PCR. PCR reactions were conducted using 1 µL pooled
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cDNA, gene-specific primers, and the following PCR settings: 98 ⁰C denaturation, 58 ⁰C
annealing, 72 ⁰C extension, 35 rounds of amplification. 1 µL of PCR product was used for
direct amplification by common primers Aga2FOR and 159REV, and the following PCR
settings: 98 ⁰C denaturation, 58 ⁰C annealing, 72 ⁰C extension, 35 rounds of amplification.
PCR product was purified using magnetic PCR purification beads (AvanBio). 90 µL beads
were added to the PCR product and supernatant was removed. Beads were washed twice
with 200 µL 70% ethanol and resuspended in 50 µL water to elute PCR products from the
beads. Beads were removed from purified PCR products. The 15bp barcode fragment was
constructed by overlap PCR. 4 primers (bc1, bc2, bc3, bc4; sequences listed below) were
mixed in equimolar ratios and used as a template for a PCR reaction using the following
PCR settings: 98 ⁰C denaturation, 55 ⁰C annealing, 72 ⁰C extension, 35 rounds of
amplification. Purified product was reamplified with the first and fourth primer using
identical PCR conditions. PCR products were run on 2% agarose gels and purified by gel
extraction (Qiagen). Purified barcode and gene products were combined with linearized
yeast-display vector (pDD003 digested with EcoRI and BamHI) and electroporated into
JAR300 yeast using a 96-well electroporator (BTX Harvard Apparatus) using the following
electroporation conditions: Square wave, 500 V, 5 ms pulse, 2 mm gap. Yeast were
immediately recovered into 1 mL liquid synthetic dextrose medium lacking uracil (SDO Ura) in 96-well deep well blocks and grown overnight at 30°C. Yeast were passaged once
by 1:10 dilution in SDO-Ura, then frozen as glycerol stocks. To construct the final library,
2.5 µL of all wells were pooled and counted. A limited dilution of 300,000 clones was subsampled and expanded in SDO-Ura. Expression was induced by passaging into synthetic
galactose medium lacking uracil (SGO-Ura) at a 1:10 dilution and growing at 30°C
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overnight. 108 yeast were pelleted and resuspended in 1 mL PBE (PBS with 0.5% BSA and
0.5 mM EDTA) containing 1:100 anti-FLAG PE antibody (BioLegend). Yeast were stained
at 4° for 75 minutes, then washed twice with 1 mL PBE and sorted for FLAG display on a
Sony SH800Z cell sorter. Sorted cells were expanded in SDO-Ura supplemented with 35
µg/mL chloramphenicol, expanded, and frozen as the final library.
bc1:TTGTTAATATACCTCTATACTTTAACGTCAAGGAGAAAAAACCCCGGATC
bc2:CTGCATCCTTTAGTGAGGGTTGAANNNNNNNNNNNNNNNTTCGATCCGG
GGTTTTTTCTCCTTG
bc3:TTCAACCCTCACTAAAGGATGCAGTTACTTCGCTGTTTTTCAATATTTTCT
GTTATTGC
bc4:TGCTAAAACGCTAGCAATAACAGAAAATATTGAAAAACAGCG

Barcode identification. Barcode-gene pairings were identified using a custom Tn5-based
sequence approach. Tn5 transposase was purified as previously described, using the oncolumn assembly method for loading oligos61. DNA was extracted from the yeast library
using Zymoprep-96 Yeast Plasmid Miniprep kits or Zymoprep Yeast Plasmid Miniprep II
kits (Zymo Research) according to standard manufacturer protocols. 5 µL of purified
plasmid DNA was digested with Tn5 in a 20 µL total reaction as previously described. 2
µL of digested DNA was amplified using primers index1 and index2, using the following
PCR settings: 98 ⁰C denaturation, 56 ⁰C annealing, 72 ⁰C extension, 25 rounds of
amplification. The product was run on a 2% gel and purified by gel extraction (Qiagen).
Purified product was amplified using primers index3 and index4, using the following PCR
settings: 98 ⁰C denaturation, 60 ⁰C annealing, 72 ⁰C extension, 25 rounds of amplification.
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In parallel, the barcode region alone was amplified using primers index1 and index5, using
the following PCR settings: 98 ⁰C denaturation, 56 ⁰C annealing, 72 ⁰C extension, 25
rounds of amplification. The product was run on a 2% gel and purified by gel extraction
(Qiagen). Purified product was amplified using primers index3 and index6, using the
following PCR settings: 98 ⁰C denaturation, 60 ⁰C annealing, 72 ⁰C extension, 20 rounds
of amplification. Both barcode and digested fragment products were run on a 2% gel and
purified by gel extraction (Qiagen). NGS library was sequenced using an Illumina MiSeq
and Illumina v3 MiSeq Reagent Kits with 150 base pair single-end sequencing according
to standard manufacturer protocols. Gene-barcode pairings were identified using custom
code. Briefly, from each read, the barcode sequence was extracted based on the
identification of the flanking constant vector backbone sequences, and the first 25 bp of
sequence immediately following the constant vector backbone-derived signal peptide were
extracted and mapped to a gene identity based on the first 25 bp of all amplified cDNA
constructs. The number of times each barcode was paired with an identified gene was
calculated. Barcode-gene pairings that were identified more than twice, with an overall
observed barcode frequency of greater than .0002% were compiled. For barcodes with
multiple gene pairings matching the above criteria, the best-fit gene was manually
identified by inspection of all barcode-gene pairing frequencies and, in general,
identification of the most abundant gene pairing. In the final library, 2,688 genes were
confidently mapped to 35,835 barcodes.

Rapid Extracellular Antigen Profiling.
Antibody purification and yeast adsorption. 20 µL protein G magnetic resin (Lytic
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Solutions) was washed twice with 100 µL sterile PBS, resuspended in 50 µL PBS, and
added to 50 µL serum or plasma. Serum-resin mixture was incubated for three hours at 4
⁰C with shaking. Resin was washed five times with 200 µL PBS, resuspended in 90 µL 100
mM glycine pH 2.7, and incubated for five minutes at room temperature. Supernatant was
extracted and added to 10 µL sterile 1M Tris pH 8.0 (purified IgG). Empty vector
(pDD003) yeast were expanded in SDO-Ura at 30 ⁰C. One day later, yeast were induced
by 1:10 dilution in SGO-Ura for 24 hours. 108 induced yeast were washed twice with 200
µL PBE (PBS with 0.5% BSA and 0.5 mM EDTA), resuspended with 100 µL purified IgG,
and incubated for three hours at 4 ⁰C with shaking. Yeast-IgG mixtures were placed into
96 well 0.45 um filter plates (Thomas Scientific) and yeast-depleted IgG was eluted into
sterile 96 well plates by centrifugation at 3000 g for 3 minutes.

Antibody yeast library selections. Transformed yeast were expanded in SDO-Ura at 30 ⁰C.
One day later, at an optical density (OD) below 8, yeast were induced by resuspension at
an OD of 1 in SGO-Ura supplemented with ten percent SDO-Ura and culturing at 30 ⁰C
for 20 hours. Prior to selection, 400 µL pre-selection library was set aside to allow for
comparison to post-selection libraries. 108 induced yeast were washed twice with 200 µL
PBE and added to wells of a sterile 96-well v-bottom microtiter plate. Yeast were
resuspended in 100 µL PBE containing appropriate antibody concentration and incubated
with shaking for 1 hour at 4 ⁰C. Unless otherwise indicated, 10 μg antibody per well was
used for human serum or plasma derived antibodies and 1 μg antibody was used for
monoclonal antibodies. Yeast were washed twice with 200 µL PBE, resuspended in 100
µL PBE with a 1:100 dilution of biotin anti-human IgG Fc antibody (clone HP6017,
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BioLegend) for human serum or plasma derived antibodies or a 1:25 dilution of biotin goat
anti-rat or anti-mouse IgG antibody (A16088, Thermo Fisher Scientific; A18869, Thermo
Fisher Scientific) for monoclonal antibodies. Yeast-antibody mixtures were incubated with
shaking for 30 minutes at 4 ⁰C. Yeast were washed twice with 200 µL PBE, resuspended
in 100 µL PBE with a 1:20 dilution of Streptavidin MicroBeads (Miltenyi Biotec), and
incubated with shaking for 30 minutes at 4 ⁰C. Yeast were then pelleted and kept on ice.
Multi-96 Columns (Miltenyi Biotec) were placed into a MultiMACS M96 Separator
(Miltenyi Biotec) and the separator was placed into positive selection mode. All following
steps were carried out at room temperature. Columns were equilibrated with 400 µL 70%
ethanol followed by 700 µL degassed PBE. Yeast were resuspended in 200 µL degassed
PBE and placed into the columns. After the mixture had completely passed through,
columns were washed three times with 700 µL degassed PBE. To elute the selected yeast,
columns were removed from the separator and placed over 96-well deep well plates. 700
µL degassed PBE was added to each well of the column and the column and deep well
plate were spun at 50 g for 30 seconds. This process was repeated 3 times. Selected yeast
were pelleted, and recovered in 1 mL SDO -Ura at 30 ⁰C.

Recombinant protein yeast library selections. All pre-selection and yeast induction steps
were performed identically as those of the antibody yeast library selections. 108 induced
yeast were washed twice with 200 µL PBE and added to wells of a sterile 96-well v-bottom
microtiter plate. Yeast were resuspended in 100 µL PBE containing 75 μL clarified protein
expression supernatant and incubated with shaking for 1 hour at 4 ⁰C. Yeast were washed
twice with 200 µL PBE, resuspended in 100 µL PBE with 5 μL μMACS Protein G
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MicroBeads (Miltenyi Biotec), and incubated with shaking for 30 minutes at 4 ⁰C.
Selection of yeast using the MultiMACS M96 Separator and subsequent steps were
performed identically as those of the antibody yeast library selections.

Next generation sequencing library preparation and sequencing. DNA was extracted from
yeast libraries using Zymoprep-96 Yeast Plasmid Miniprep kits or Zymoprep Yeast
Plasmid Miniprep II kits (Zymo Research) according to standard manufacturer protocols.
A first round of PCR was used to amplify a DNA sequence containing the protein display
barcode on the yeast plasmid. PCR reactions were conducted using 1 µL plasmid DNA,
159_DIF2 and 159_DIR2 primers (sequences listed below), and the following PCR
settings: 98 ⁰C denaturation, 58 ⁰C annealing, 72 ⁰C extension, 25 rounds of amplification.
PCR product was purified using magnetic PCR purification beads (AvanBio). 45 µL beads
were added to the PCR product and supernatant was removed. Beads were washed twice
with 100 µL 70% ethanol and resuspended in 25 µL water to elute PCR products from the
beads. Beads were removed from purified PCR products. A second round of PCR was
conducted using 1 µL purified PCR product, Nextera i5 and i7 dual-index library primers
(Illumina), and the following PCR settings: 98 ⁰C denaturation, 58 ⁰C annealing, 72 ⁰C
extension, 25 rounds of amplification. PCR products were pooled and run on a 1% agarose
gel. The band corresponding to 257 base pairs was cut out and DNA (NGS library) was
extracted using a QIAquick Gel Extraction Kit (Qiagen) according to standard
manufacturer protocols. NGS library was sequenced using an Illumina MiSeq and Illumina
v3 MiSeq Reagent Kits with 75 base pair single-end sequencing or using an Illumina
NovaSeq 6000 and Illumina NovaSeq S4 200 cycle kit with 101 base pair paired-end
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sequencing according to standard manufacturer protocols. A minimum of 50,000 reads per
sample was collected and the pre-selection library was sampled at ten times greater depth
than other samples.
159_DIF2:TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNNNNNNNGA
GAAAAAACCCCGGATCG
159_DIR2:GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGNNNNNNNNNNA
CGCTAGCAATAACAGAAAATATTG

Data analysis. REAP scores were calculated as follows. First, barcode counts were
extracted from raw NGS data using custom codes and counts from technical replicates were
summed. Next, aggregate and clonal enrichment was calculated using edgeR62 and custom
codes. For aggregate enrichment, barcode counts across all unique barcodes associated
with a given protein were summed, library sizes across samples were normalized using
default edgeR parameters, common and tagwise dispersion were estimated using default
edgeR parameters, and exact tests comparing each sample to the pre-selection library were
performed using default edgeR parameters. Aggregate enrichment is thus the log2 fold
change values from these exact tests with zeroes in the place of negative fold changes.
Log2 fold change values for clonal enrichment were calculated in an identical manner, but
barcode counts across all unique barcodes associated with a given protein were not
summed. Clonal enrichment for a given reactivity was defined as the fraction of clones out
of total clones that were enriched (log2 fold change ≥ 2). Aggregate (
enrichment (

) for a given protein, a scaling factor (

) and clonal

) based on the number of unique

yeast clones (yeast that have a unique DNA barcode) displaying a given protein, and a
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scaling factor (

) based on the overall frequency of yeast in the library displaying a given

protein were used as inputs to calculate the REAP score, which is defined as follows.

and

are logarithmic scaling factors that progressively penalize the REAP score of

proteins with low numbers of unique barcodes or low frequencies in the library.
applied to proteins with ≤ 5 unique yeast clones in the library and
with a frequency ≤ 0.0001 in the library.

is

is applied to proteins

was implemented to mitigate spurious

enrichment signals from low frequency proteins, which could occur due to sequencing
errors or stochasticity in the selection process.

was implemented because the clonal

enrichment metric is less valid for proteins with low numbers of unique yeast clones,
decreasing confidence in the validity of the reactivity.
where

and

are defined as follows

is the number of unique yeast clones for a given protein and

is the log10

transformed frequency of a given protein in the library.

Recombinant protein production.
REAP recombinant protein production. Proteins were produced as human IgG1 Fc fusions
to enable binding of secondary antibody and magnetic beads to the produced proteins
during the REAP process. Sequences encoding the extracellular portions of proteins-ofinterests that were present in the yeast display library were cloned by Gibson assembly into
a modified pD2610-v12 plasmid (ATUM). Modifications include addition of an H7 signal
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sequence followed by a (GGGGS)3 linker and a truncated human IgG1 Fc (N297A).
Protein-of-interest sequences were inserted directly downstream of the H7 leader sequence.
Protein was produced by transfection into Expi293 cells (Thermo Fisher Scientific) in 96well plate format. One day prior to transfection, cells were seeded at a density of 2 million
cells per mL in Expi293 Expression Medium (Thermo Fisher Scientific). In a 96-well plate,
0.5 μg plasmid DNA was diluted added to 25 μL Opti-MEM (Thermo Fisher Scientific)
and mixed gently. In a separate 96-well plate, 1.35 μL ExpiFectamine was added to 25 μL
Opti-MEM and mixed gently. The ExpiFectamine-Opti-MEM mixture was added to the
diluted DNA, mixed gently, and incubated for 20 minutes at room temperature. Expi293
cells were diluted to a density of 2.8 million cells per mL and 500 μL of cells were added
to each well of a 96-well deep well plate. 50 μL of the DNA-ExpiFectamine-Opti-MEM
mixture was added to each well. The plate was sealed with Breathe-Easier sealing film
(Diversified Biotech) and incubated in a humidified tissue culture incubator (37 ⁰C, 8%
CO2) with shaking at 1,200 rpm so that cells were kept in suspension. 18-20 hours posttransfection, 25 μL enhancer 2 and 2.5 μL enhancer 1 (Thermo Fisher Scientific) were
added to each well. 4 days post-transfection, media was clarified by centrifugation at 30004000 g for 5 minutes. Clarified media was used for recombinant protein REAP.

ELISA protein production. Sequences encoding the extracellular portions of proteins-ofinterests that were present in the yeast display library were cloned by Gibson assembly into
pEZT_Dlux, a modified pEZT-BM vector. The pEZT-BM vector was a gift from Ryan
Hibbs (Addgene plasmid #74099). Modifications included insertion of an H7 Leader
Sequence followed by an AviTag (Avidity), HRV 3C site, protein C epitope, and an 8x his
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tag. Protein-of-interest sequences were inserted directly downstream of the H7 leader
sequence. Protein was produced by transfection into Expi293 cells (Thermo Fisher
Scientific) according to standard manufacturer protocols. Transfected cells were
maintained according to manufacturer protocols. 4 days post-transfection, media was
clarified by centrifugation at 300 g for 5 minutes. Protein was purified from clarified media
by nickel-nitrilotriacetic acid (Ni-NTA) chromatography and desalted into HEPES
buffered saline + 100 mM sodium chloride, pH 7.5. Protein purity was verified by SDSPAGE.

Biotinylated protein production. Sequences encoding the extracellular portions of proteinsof-interests were cloned into pEZT_Dlux as described above. Protein was expressed and
purified as described above minus desalting. Enzymatic biotinylation with BirA ligase was
performed and protein was purified by size-exclusion fast protein liquid chromatography
using a NGC Quest 10 Chromatography System (Bio-Rad).

LIPS protein production. Sequences encoding Lucia luciferase (InvivoGen) fused by a
GGSG linker to the N-terminus of the protein-of-interest extracellular portion (as defined
above) were cloned by Gibson assembly into pEZT-BM. Protein was produced by
transfection into Expi293 cells (Thermo Fisher Scientific) according to standard
manufacturer protocols. Transfected cells were maintained according to manufacturer
protocols. 3 days post-transfection, media was clarified by centrifugation at 300 g for 5
minutes. Clarified media was used in luciferase immunoprecipitation systems assays.
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Enzyme-linked immunosorbent assays (ELISAs).
200 or 400 ng of purchased or independently produced recombinant protein in 100 µL of
PBS pH 7.0 was added to 96-well flat bottom Immulon 2HB plates (Thermo Fisher
Scientific) and placed at 4 ⁰C overnight. Plates were washed once with 225 µL ELISA
wash buffer (PBS + 0.05% Tween 20) and 150 µL ELISA blocking buffer (PBS + 2%
Human Serum Albumin) was added to the well. Plates were incubated with shaking for 2
hours at room temperature. ELISA blocking buffer was removed from the wells and
appropriate dilutions of sample serum in 100 µL ELISA blocking buffer were added to
each well. Plates were incubated with shaking for 2 hours at room temperature. Plates were
washed 6 times with 225 µL ELISA wash buffer and 1:5000 goat anti-human IgG HRP
(Millipore Sigma) or anti-human IgG isotype specific HRP (Southern Biotech; IgG1: clone
HP6001, IgG2: clone 31-7-4, IgG3: clone HP6050, IgG4: clone HP6025) in 100 µL ELISA
blocking buffer was added to the wells. Plates were incubated with shaking for 1 hour at
room temperature. Plates were washed 6 times with 225 µL ELISA wash buffer. 50 µL
TMB substrate (BD Biosciences) was added to the wells and plates were incubated for 15
minutes (pan-IgG ELISAs) or 20 minutes (isotype specific IgG ELISAs) in the dark at
room temperature. 50 µL 1 M sulfuric acid was added to the wells and absorbance at 450
nm was measured in a Synergy HTX Multi-Mode Microplate Reader (BioTek).

Luciferase immunoprecipitation systems (LIPS) assays.
Pierce Protein A/G Ultralink Resin (5 µL; Thermo Fisher Scientific) and 1 µL sample
serum in 100 µL Buffer A (50 mM Tris, 150 mM NaCl, 0.1% Triton X-100, pH 7.5) was
added to 96-well opaque Multiscreen HTS 96 HV 0.45 um filter plates (Millipore Sigma).
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Plates were incubated with shaking at 300 rpm for 1 hour at room temperature. Supernatant
in wells was removed by centrifugation at 2000 g for 1 minute. Luciferase fusion protein
(106 RLU) was added to the wells in 100 µL Buffer A. Plates were incubated with shaking
at 300 rpm for 1 hour at room temperature. Using a vacuum manifold, wells were washed
8 times with 100 µL Buffer A followed by 2 washes with 100 µL PBS. Remaining
supernatant in wells was removed by centrifugation at 2000 g for 1 minute. Plates were
dark adapted for 5 minutes. An autoinjector equipped Synergy HTX Multi-Mode
Microplate Reader (BioTek) was primed with QUANTI-Luc Gold (InvivoGen). Plates
were read using the following per well steps: 50 µL QUANTI-Luc Gold injection, 4 second
delay with shaking, read luminescence with an integration time of 0.1 seconds and a read
height of 1 mm.

PD-L2 blocking assay.
A single clone of PD-L2 displaying yeast was isolated from the library and expanded in
SDO-Ura at 30 ⁰C. Yeast were induced by 1:10 dilution into SGO-Ura and culturing at 30
⁰C for 24 hours. 105 induced PD-L1 yeast were washed twice with 200 μL PBE and added
to wells of a 96-well v-bottom microtiter plate. Yeast were resuspended in 25 μL PBE
containing serial dilutions of sample serum and incubated with shaking for 1 hour at 4 ⁰C.
PD-1 tetramers were prepared by incubating a 5:1 ratio of biotinylated PD-1 and PE
streptavidin (BioLegend) for 10 minutes on ice in the dark. Yeast were washed twice with
200 μL PBE, resuspended in 25 μL PBE containing 10 nM previously prepared PD-1
tetramers, and incubated with shaking for 1 hour at 4 ⁰C. Yeast were washed twice with
200 μL PBE and resuspended in 75 μL PBE. PE fluorescent intensity was quantified by
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flow cytometry using a Sony SA3800 Spectral Cell Analyzer. Percent max binding was
calculated based on fluorescent PD-1 tetramer binding in the absence of any serum.

IL-33 neutralization assay.
IL-33 reporter cell line construction. The full-length coding sequence for ST2 was cloned
by Gibson assembly into the lentiviral transfer plasmid pL-SFFV.Reporter.RFP657.PAC,
a kind gift from Benjamin Ebert (Addgene plasmid #61395). HEK-293FT cells were
seeded into a 6-well plate in 2 mL growth media (DMEM with 10% (v/v) FBS, 100
units/mL penicillin, and 0.1 mg/mL streptomycin) and were incubated at 37°C, 5% CO2.
Once cells achieved 70-80% confluence approximately one day later, cells were transfected
using TransIT-LT1 (Mirus Bio) in Opti-MEM media (Life Technologies). TransIT-LT1
Reagent was pre-warmed to room temperature and vortexed gently. For each well, 0.88 ug
lentiviral transfer plasmid along with 0.66 ug pSPAX2 (Addgene plasmid #12260) and
0.44 ug pMD2.G (Addgene plasmid #12259), kind gifts from Didier Trono, were added to
250 μL Opti-MEM media and mixed gently. TransIT-LT1 reagent (6 μl) was added to the
DNA mixture, mixed gently, and incubated at room temperature for 15-20 minutes. The
mixture was added dropwise to different areas of the well. Plates were incubated at 37°C,
5% CO2; 48hrs later, the virus-containing media was collected and filtered with a 0.45μm
low protein-binding filter. HEK-Blue IL-18 cells (InvivoGen) were seeded into a 6-well
plate in 1 mL growth media (DMEM with 10% (v/v) FBS, 100 units/mL penicillin, and 0.1
mg/mL streptomycin) and 1 mL virus-containing media. Cells were incubated at 37°C, 5%
CO2 for two days before the media was changed.
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Reporter cell stimulation and reading. Purified IgG titrations and 2 nM IL-33 were mixed
in 50 µL assay media (DMEM with 10% (v/v) FBS, 100 units/mL penicillin, and 0.1
mg/mL streptomycin) and incubated with shaking for 1 hour at room temperature.
Approximately 50,000 IL-33 reporter cells in 50 µL assay media were added to wells of a
sterile tissue culture grade flat-bottom 96-well plate. IgG-IL-33 mixtures were added to
respective wells (1 nM IL-33 final concentration). Plates were incubated at 37°C, 5% CO2
for 20 hours, then 20 µL media from each well was added to 180 μL room temperature
QUANTI-Blue Solution (InvivoGen) in a separate flat-bottom 96-well plate and incubated
at 37°C for 3 hours. Absorbance at 655 nm was measured in a Synergy HTX Multi-Mode
Microplate Reader (BioTek). Percent max signal was calculated based on signal generated
by IL-33 in the absence of any serum.

ROC analysis of REAP score performance.
Orthogonal validation data for the receiver operator curve (ROC) analysis was obtained by
ELISA, LIPS, or clinical autoantibody tests. For ELISA and LIPS, valid reactivities were
defined as those 3 standard deviations above the healthy donor average for a given protein
in each assay. ROC analysis was performed using 247 test pairs across 25 different
proteins. A full list of ROC inputs can be found in Supplementary Data 1 (available at
https://www.biorxiv.org/content/10.1101/2021.02.11.430703v1.supplementary-material).

Patient Samples
SLE patients. Collection of SLE patient blood samples was approved by the Yale Human
Research Protection Program Institutional Review Boards (protocol ID 1602017276). All
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patients met the 2012 SLICC classification criteria for SLE63. Clinical information was
gathered via retrospective EMR review. Informed consent was obtained from all patients.

APECED patients. Collection of APECED patient blood samples was performed under a
NIAID IRB-approved prospective natural history study (11-I-0187, NCT01386437).
Patients underwent a comprehensive clinical evaluation at the NIH Clinical Center
including a detailed history and physical examination, laboratory and radiologic
evaluations and consultations by a multidisciplinary team of specialists including
infectious disease, immunology, genetics, endocrinology, gastroenterology, hepatology,
pulmonology, dermatology, dental, and ophthalmology, as previously described64. All
study participants provided written informed consent.

Statistical analysis.
Statistical details of experiments can be found in the figure legends. All REAP screens and
experimental assays were performed with technical replicates. Data analysis was
performed using R, Python, Excel, and GraphPad Prism. Unless otherwise specified,
adjustment for false discovery rate was performed using the Benjamini-Hochberg
procedure.

Data Availability
Data are available from the corresponding author upon reasonable request.

Code Availability
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All code will be available at GitHub.
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Figure 2 | REAP screen of APECED patients. A cohort of 77 APECED patients and 20 healthy controls were screened using
REAP. a, Heatmap of REAP scores. Antigen groups were manually categorized. b,
healthy donor average score plus 3 standard deviations) against 14 antigens based on REAP and prior literature
. c, Violin
plot of GIF REAP scores in APECED samples stratified by intrinsic factor clinical autoantibody test results. d, EC50 of fitted REAP
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Figure 3 | REAP screen of SLE patients. A cohort of 106 unique SLE patients spanning 155 samples and 20 healthy controls
was screened using REAP. a, Heatmap of REAP scores where each column is a unique patient. For patients with longitudinal
samples, the maximum REAP score for each given reactivity is shown. Antigen groups were manually categorized. Patients are
ordered from left to right by increasing SLEDAI score. White stars symbolize detection of a therapeutic antibody. Score was
artificially capped at 7 to aid visualization. b, Violin plots of the number of reactivities in SLE samples stratified by disease severity
and control samples at a score cutoff of 3. Significance was determined using a Kruskal-Wallis test followed by a Dunnett’s test. c,
Heatmap of false discovery rate-adjusted p-values from two-sided Mann-Whitney U tests comparing REAP score distributions for
specific proteins between patients stratified by disease manifestations. Only reactivities positive in at least 3 patients were tested.
d, SLEDAI scores for SLE patients stratified by reactivity against CCL8. e, SLEDAI scores for SLE patients positive or negative by
REAP score for reactivities against immunoregulatory antigens (defined in a). f, anti-PD-L2 and i, anti-IL-33 pan-IgG ELISAs
conducted with serial dilutions of SLE or control serum. g, schematic and h, results of PD-L2 blocking assay conducted with serial
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Table 1

Table 1 | Orthogonal validation of SLE autoantibody
reactivities identified in REAP.
Antigen

# Candidate
Samples
Tested

REAP Score
Range

# Validated
by ELISA or
LIPS

VEGF-B
IFN- 17

10

1.67 - 8.88

10

8

1.85 - 10.33

8

IFN- 8

7

1.13 - 8.92

4

FAS

6

1.73 - 4.95

4

EPYC

4

4.93 - 9.46

4

CSPG5

6

1.64 - 5.92

3

IL-6

3

3.60 - 7.82

3

PD-L2

4

2.43 - 9.69

2

IL-4

2

5.78 - 6.09

2

CCL8

4

4.59 - 6.44

1

IL-33

1

3.88

1

IL-18R

1

3.3

1

IL-16

1

4.03

1

LILRB4

1

3.85

1

ACVR2B

1

8.56

1

IER3

1

4.23

1

IFNL2

6

3.27 - 7.74

0

NGFR

4

3.40 - 6.73

0

RGMB

4

4.15 - 5.49

0

CD44

1

6.34

0

RAET1E

1

7.6

0
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Supplementary Figure 1 | Exoproteome yeast display library properties. a, Flowchart of steps in identification and annotation
of extracellular or secreted proteins for inclusion in the library. b, Pie chart of all extracellular or secreted proteins identified in a.
Proteins were not attempted if they had an ectodomain less than 50 amino acids or less than 600 amino acids. c, Percent of
proteins displayed in each protein family included in the library. The dotted line represents the aggregate display level in the
library. Abbreviations are as follows: immunoglobulin superfamily (IgSF), epidermal growth factor (EGF), fibronectin (Fn),
leucine-rich repeat (LRR), urokinase receptor (UPAR), c-type lectin (CLEC), tetraspanin (TSPAN). The cytokine family consists of
proteins belonging to tumor necrosis factor, interferon, interleukin, and growth factor protein families. d, Box plot of Log2[fold
enrichment] R² coefficient of determination values between technical replicates of APECED patients screened in figure 2. e,
REAP versus f, ELISA dose-response curve comparison for APECED autoantibodies against four proteins. REAP data is from a
screen conducted using varying concentrations of AIRE.19 IgG. Curves were fit using a sigmoidal 4 parameter logistic curve. For
REAP, curves were fit based on Log [fold enrichment]. For ELISA, curves were fit based on optical density at 450 nm. Error bars
represent standard error of the mean. g, Comparison of autoantibody detection frequencies in APECED patient cohorts by REAP,
LIPS18, ProtoArray18, and PhIP-Seq21. Frequencies are listed as a percentage inside each circle. Size and color of circles are
proportional to detection frequency. For REAP, detection frequency was calculated as in figure 2b. For LIPS and ProtoArray,
detection frequencies were provided in the corresponding publication. For PhIP-Seq, detection frequency was calculated based on
figures in the corresponding publication. For reactivities labelled n.d., either data was not publicly available or the autoantibody
was not tested for in the corresponding assay.
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Supplementary Figure 2 | APECED and SLE reactivity distributions. a, Violin plots of the number of reactivities in APECED
and control samples at a score cutoff of 1 or 2. b, Mean number of reactivities in APECED and control samples at various score
cutoffs, along with indicators of significance. c, Violin plots of the number of reactivities in SLE samples stratified by disease
severity and control samples at a score cutoff of 1 or 2. d, Mean number of reactivities in SLE samples stratified by disease
severity and control samples at various score cutoffs. Comparisons were made between each disease severity group and the
control group. Significance in a and b was calculated using a two-sided Mann-Whitney U test. Significance in c and d was determined using a Kruskal-Wallis test followed by a Dunnett’s test.
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Supplementary Figure 3 | REAP validation and ROC analysis. a-l, Single-point ELISAs or LIPS conducted with SLE,
APECED, or control serum to detect autoantibodies against ACVR2B (a), CCL8 (b), CSPG5 (c), CXCL3 (d), Fas (e), IL-4 (f), IL-6
(g), IL-16 (h), IL-22 (i
j
k), and IFNL2 (l). Serum dilutions are listed in the title of each plot. m-r, ELISAs or
LIPS conducted with serial dilutions of SLE, APECED, or control serum to detect autoantibodies against BPIFA2 (m), EPYC (n),
IER3 (o), IL18RAP (p), LILRB4 (q), and VEGF-B (r). Dotted lines in a-l represent the control average + 3 standard deviations. s,
Receiver operating characteristic curve of the ability of REAP score to predict validation of a REAP reactivity in an orthogonal
assay. A full description of this analysis can be found in the materials and methods section. t, Anti-epiphycan IgG subclass
specific ELISA conducted with serial dilutions of serum from the SLE patient with highest titers in n. u, Anti-IL-18RAcP subclass
specific ELISA conducted with serial dilutions of serum from the SLE patient in p. v, Anti-PD-L2 IgG subclass specific ELISAs
conducted with serial dilutions of serum from the SLE patient in figure 3f. All error bars in this figure all represent standard
deviation. All curves in this figure were fit using a sigmoidal 4 parameter logistic curve.

117

Supplementary Table 2
Supplementary Table 2 | APECED patient demographics and clinical
characteristics.
APECED cohort characteristics (n = 77)
Age*
Gender (female)
Ethnicity
White Non-Hispanic
White/Hispanic
AIRE alleles**
c.967_979del13
c.769C>T
Clinical manifestations
Chronic mucocutaneous candidiasis
Adrenal insufficiency
Hypoparathyroidism
Hypothyroidism
Hypogonadism
Autoimmune pneumonitis
Autoimmune hepatitis
Intestinal dysfunction
Exocrine pancreatic insufficiency
Asplenia
Alopecia
Vitiligo
Sjogren's-like syndrome
Autoimmune gastritis
B12 deficiency
Intrinsic factor antibody
Lung-targeted autoantibodies***
BPIFB1
KCNRG

Number (%)
24 (14.4)
45 (58)
68 (88)
5 (7)
79 (51)
21 (14)
66 (86)
62 (81)
63 (82)
18 (23)
26 (34)
28 (36)
25 (33)
53 (69)
1 (1)
10 (13)
26 (34)
19 (25)
30 (39)
30 (39)
20 (26)
24 (31)
19 (26)
4 (6)

*Age is represented as mean (standard deviation) in years
**The denominator for AIRE mutant alleles is 154
***Data available for 72 patients
AIRE, autoimmune regulator; APECED, autoimmune polyendocrinopathycandidiasis-ectodermal dystrophy; BPIFB1, BPI fold containing family B member 1
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Supplementary Table 3
Supplementary Table 3 | SLE patient and control demographics and clinical
characteristics.

Mean (SD) or as indicated
Age, (years)
Gender, N (% female)
Ethnicity, N (%)
Hispanic
Non-Hispanic
African American
Clinical Manifestations, N (%)
Skin
Mucocutaneous
Musculoskeletal
Renal
Cardiorespiratory
Hematological
Neuropsychiatric
Serologies, N (%)
Positive dsDNA
Low complement
SLEDAI score
Medications, any use N (%)
Prednisone
Hydroxychloroquine
Mycophenolate mofetil
Methotrexate
Azathioprine
Belimumab
Others (cyclophosphamide,
rituximab, tacrolimus, infliximab, etc.)

SLE Cohort
(n = 85*)
41.7 (12.6)
76 (89.4)

Healthy Controls
(n = 20)
37.2 (11)
12 (60)

22 (26)
35 (41)
28 (33)

3 (15)
8 (40)
9 (45)

40 (47.1)
16 (18.8)
29 (34.1)
20 (23.5)
4 (4.7)
7 (8.2)
0 (0)
40 (47.1)
34 (40)
6.3 (6.1)
40 (47.1)
72 (84.7)
24 (28.2)
6 (7.1)
4 (4.7)
6 (7.1)
10.6%

Abbreviations: SLEDAI (Systemic Lupus Erythematosus Disease Activity Index).
Prednisone dosing ranges from 5 mg daily to 60 mg daily.
*Complete clinical data was not available for a subset of patients. A total of 106 patients
were screened.
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Chapter 4: A host-microbiota interactome atlas reveals extensive transkingdom
connectivity
Connor E. Rosen, Nicole Sonnert, Yile Dai, Eric Wang, Jason Bishai, Tyler Rice, Jaime
Gonzales-Hernandez, Changhui Guan, Agata A. Bielecka, Suzanne Fischer, Julia Oh,
Aaron M. Ring, Noah W. Palm

ABSTRACT
The myriad bacteria that live in and on us have diverse impacts on human physiology, yet
the molecular details underlying host-microbiota interactions remain largely unknown.
To map the host-microbiota interactome, we developed a novel technology called
BASEHIT that enables comprehensive evaluation of interactions between an individual
bacterial strain and thousands of human extracellular proteins. Using BASEHIT, we
evaluated 1.28 million potential interactions between 477 phylogenetically and
functionally diverse human-associated bacterial strains and 2,688 human extracellular
proteins. The resulting host-microbiota interactome atlas contains >3,000 previously
undiscovered interactions that may contribute to tissue colonization, immunomodulation,
and strain-specific impacts on human disease. By dramatically expanding the landscape
of known host-microbiota interactions, this atlas will facilitate molecular dissection of the
microbiota's influence on human biology.

MAIN TEXT
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The bacterial microbiota has profound impacts on nearly all aspects of human biology,
from regulating immunity in the gut to shaping mood and behavior, though the molecular
bases of these effects remain largely elusive1-4. Recent studies have revealed important
roles of small-molecule metabolites in influencing host (patho)physiology5-8. By contrast,
the interactions between the microbiota and host extracellular/secreted proteins (the
“exoproteome”) remain largely unexplored. This is in spite of the numerous ways that the
microbiota can potentially interface with the host exoproteome. For example, secreted
proteins can bind microbes that are separated from the host epithelium by physiochemical
barriers, and resident microbes that breach these barriers directly contact the host
epithelial surface and apically expressed proteins9-10. Furthermore, microbial
translocation beyond the epithelium to local and sometimes even distant tissues has
recently emerged as a common feature of various pathophysiological states, including
metabolic syndrome, autoimmunity, cancer, and aging11-13. Thus, indigenous microbes
have innumerable opportunities to encounter diverse members of the host exoproteome,
well beyond obvious binding partners at barrier surfaces.

Understanding host exoproteome:microbiota interactions may reveal the mechanisms by
which indigenous microbes colonize host-associated niches and modulate host responses
and thereby provide key insights into the role of specific host-associated microbes in
human health and disease. However, a deeper understanding of direct host-microbe
interactions has been hampered by a lack of tools for unbiased detection of microbial
interactions with extracellular host proteins14-16. We thus sought to develop a novel
method to enable mapping of host-microbiota interactions across the entire human
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exoproteome and to create a draft “atlas” of host:microbe interactions spanning diverse
bacterial phylogenies and host tissues.

BASEHIT: a tool to discover bacterial interactions with the host exoproteome
We developed and optimized a high-throughput technology to screen intact microbial
cells for the ability to bind human proteins displayed on the surface of yeast, which we
call BASEHIT (BActerial Selection to Elucidate Host-microbe Interactions in high
Throughput, Fig. 4.1A). The BASEHIT process involves surface biotinylation of
bacterial cells, incubation of the labeled bacteria with genetically-barcoded yeast clones
that display individual human extracellular proteins, isolation of bacteria:yeast
complexes, and next-generation sequencing of the barcodes encoded by the enriched
yeast clones. Using these data, we derive a “BASEHIT score” that represents the
predicted degree of interaction between an individual microbe and a given host protein on
the basis of the differential enrichment of the protein’s corresponding barcodes after
selection (see methods).

We first optimized and validated the conditions for protein-dependent, bacteria:yeast
complex formation and isolation using a gold-standard host-microbe interaction,
Staphylococcus aureus binding to human IgG Fc17. The BASEHIT process specifically
enriched Fc-expressing yeast clones by approximately 50-fold from a mixture of GFPlabeled IgG Fc-expressing yeast and a large excess of yeast expressing irrelevant control
human proteins (Fig. 4.1B). This result thus confirmed that bacteria:yeast complex
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formation was strongly dependent on the expression of a relevant host ligand and that the
magnetic selection process enables robust enrichment.

To enable comprehensive evaluation of potential bacterial binding to the human
exoproteome, we created a curated, barcoded library of 3,100 human extracellular and
secreted proteins displayed clonally on the surface of yeast. This library covers over 50%
of the total human exoproteome and includes a broad range of transmembrane, secreted,
and membrane-associated proteins with diverse protein folds, expression patterns, and
biological functions. Because yeast are not capable of expressing all human exoproteins,
we selected for clones that successfully displayed protein on their surface through
fluorescence-activated cell sorting (FACS) of FLAG epitope tag (which is only present
on yeast clones that express full-length proteins). Greater than 86% of proteins (2,688)
remained in the library after FACS selection, which were present with a roughly flat
distribution of frequencies and represented by approximately 15 unique barcodes each.
We thus used this library for interactome mapping in subsequent studies.

To evaluate the potential of BASEHIT to map host:bacterial interactions using this
library, we assessed the interactome of an adherent-invasive Escherichia coli (AIEC)
isolate that expresses a Dr-family adhesin and binds to the host cell surface proteins
CD55 and CEACAM118-19. As a control, we simultaneously profiled several other E. coli
strains lacking these adhesins. As seen in Fig. 4.1C, BASEHIT accurately identified
CD55 and CEACAM1 as the top predicted binding partners for AIEC, whereas control E.
coli strains demonstrated no detectable binding to these proteins (Fig. 4.1D).
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Discovery and validation of novel host:microbiota interactions using BASEHIT
We used BASEHIT to map the landscape of host-microbiota interactions for a large
collection of human-associated bacteria representing diverse phylogenies and
biogeographical niches. We assembled and screened a collection of 477 bacterial strains
from the human microbiota isolated from the mouth, gut, lung, skin, vagina, and blood
that encompassed 6 phyla, 44 families, and 59 genera20-22. This collection also included
multiple strains from 34 species to evaluate the impact of strain variation on hostmicrobiota interactions. In total, we interrogated approximately 1.3 million potential
binary interactions between individual host proteins and unique bacterial strains and
identified 2,949 predicted binding events that passed the conservative BASEHIT score
cutoff of 5 (Fig. 4.2A; see methods for a detailed description of BASEHIT scoring).

The total number of proteins bound by each isolate was highly variable and largely
independent of phylogeny. Overall, the number of predicted interactions per strain
spanned two orders of magnitude, from zero detected interactions to over 100 (Fig.
4.2B). While the majority of strains (348 out of 477, 73%) interacted with 5 or fewer host
proteins, 16 strains bound to more than 30. These “superbinder” strains were derived
from diverse tissues and phylogenies. Notably, two superbinder strains from the intestine
(an Erysipelotrichaceae strain and a Proteus mirabilis strain) have been previously
shown to cause severe intestinal inflammation in mouse models of inflammatory bowel
disease23-24. This suggests that the patterns of host protein interaction may predict
pathogenic potential.
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Interaction patterns also varied widely across protein families and folds. For example,
1,816 (68%) of the 2,688 proteins in the exoprotein library failed to interact significantly
with any bacterial strains, 362 proteins interacted with only one or two strains, and 18
proteins (0.7%) interacted with 10 or more strains (Fig. 4.2C). The lack of predicted
interactions for most proteins was not due to failed expression or aberrant folding of
those specific proteins as many non-interacting proteins were readily detected in the yeast
library via staining with specific antibodies (Chapter 3).

Overall, the BASEHIT screen predicted thousands of previously undiscovered molecularlevel host:microbe interactions, dramatically expanding the known universe of potential
mechanisms through which indigenous microbes interface with and may impact the host.
These interactions were distributed across diverse phyla (Fig. 4.2D) and tissues of origin
of the bacteria evaluated. Furthermore, the interactions involved a multitude of hostprotein families with varied cellular localizations and tissue expression patterns. To
evaluate the predictive value of the BASEHIT screening results, we selected 64 putative
interactions across a broad distribution of bacterial phylogenies and protein types to
validate using orthogonal approaches. We validated 49 of these interactions via flow
cytometry or ELISA (Fig. 4.2E, F), demonstrating that BASEHIT accurately identifies
novel host-microbe interactions with high confidence. We hypothesize that this may
represent a conservative estimate of the true predictive value of BASEHIT; indeed, due to
the high density of expression of receptor:ligand pairs on the yeast and bacterial cell
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surfaces, BASEHIT may be capable of detecting low-affinity, high-avidity interactions
that are otherwise too weak to be detected by conventional approaches.

A draft atlas of the host-microbiota interactome
The BASEHIT process enables facile determination of host-microbe interactome
“fingerprints” for hundreds of individual bacterial strains. We thus used the 477 unique
interactomes determined via BASEHIT to assemble an expansive host
exoproteome:microbiota interactome atlas that surveys the diverse landscape of bacteria
contained within the collective human microbiota. This interactome atlas facilitated the
direct comparison of hundreds of host-associated bacterial strains based on patterns of
interaction with host exoproteins rather than microbial phylogenies. Nonlinear
dimensionality reduction based on individual strain-specific interactomes revealed
diverse patterns of interaction across taxa that distributed across several clusters (Fig.
4.3A). The majority of strains localized to a diffuse central cluster (cluster 1), reflecting
the relative uniqueness of individual microbial interactomes and a lack of common host
interaction partners among most strains. However, some discrete interaction patterns also
emerged in the form of 3 additional clusters, which are characterized by distinct
modalities of microbial interaction with the host. Specifically, a group of
Propionibacterium acnes strains formed a unique cluster (cluster 2), a subset of
Staphylococcus strains (cluster 3), and a mixed-cluster that was dominated by Klebsiella
strains, but also contained representatives from Actinobacteria, Firmicutes, and
Fusobacteria (cluster 4).
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Divergent host protein binding patterns imply functional variation between
phylogenetically-related bacterial strains
Bacterial strains assigned to the same species can exhibit divergent impacts on host
physiology25-27. In principle, strain-specific interactions with the exoproteome could
contribute to such functional variation. To assess the degree of heterogeneity in host
protein binding between bacterial strains, we first compared the interactomes of 148 skinderived isolates from five common Staphylococcus species. Multiple Staphylococcus
strains interacted with skin-expressed proteins, including the corneodesmosome proteins
CDSN and KLK7, junctional proteins CLDN4 and FAT2, and the secreted protein
SLURP1 (Fig. 4.4A). Among these proteins, CDSN, FAT2, and SLURP1 were uniquely
recognized by skin-derived Staphylococcus isolates and not by any other strain in the
BASEHIT atlas. However, exoprotein-binding patterns still varied dramatically both
within and between Staphylococcus species, and even the most common interactions
were observed in less than ten percent of all Staphylococcus strains. Importantly, strain
variation in host-protein binding was not due to technical variation in BASEHIT since
differential binding was also observed via bacterial flow cytometry.

We next focused on two bacterial taxa from the gut microbiota that are associated with
distinct human pathologies, the genus Fusobacterium and the species Ruminococcus
gnavus. Fusobacterium species are enriched in tumors28-30 and specific Fusobacterium
nucleatum strains modulate host immunity through direct interactions with TIGIT and
CEACAM131-33. The seventeen Fusobacterium strains in the BASEHIT atlas spanned
five tissues of origin. However, nearly all Fusobacterium isolates bound to at least one
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known immunomodulatory host protein, including two ITIM-coupled
immunosuppressive proteins (SIRPA and LAIR1), four cytokine receptors (IL15RA,
IL13RA1, IL10RB, and IL9R), and four cytokines (CSF3, IFNB1, IL10, IL33) (Fig.
4.4B). These interactions further underscore the immunomodulatory potential of this
genus and provide molecular insights into the potential role of Fusobacterium in
tumorigenesis and modulation of the immune tumor microenvironment.

R. gnavus is enriched in inflammatory bowel disease (IBD) subjects and strain-level
variation and “clade switching” in R. gnavus are closely associated with IBD flares34-36.
Examination of R. gnavus isolates in the BASEHIT atlas revealed strain-variable
interactions with multiple immunoreceptors expressed on T cells, including CD7,
TNFRSF1B, TNFRSF4, TNFRSF7, TNFRSF9, and TMEM149, as well as the mucusassociated trefoil factors TFF1 and TFF2 (Fig. 4.4C). Interestingly, these interactions
were most evident in isolates derived from IBD patients, which we confirmed for CD7 by
flow cytometry (Fig. 4.4D). R. gnavus-CD7 interactions were also highly host-specific as
mouse CD7 failed to bind to human R. gnavus (Fig. 4.4E). These interactions provide
new insights into the mechanisms by which R. gnavus may modulate immune-mediated
disease in humans and demonstrate that direct interactions between commensal microbes
and defined host receptors can exhibit host-species specificity.

Discussion
Here, we describe a novel technology that enables comprehensive mapping of
host:bacteria interactomes across hundreds of bacterial strains and the generation of a
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draft host-microbiota interactome atlas. This atlas describes thousands of previously
undiscovered connections between indigenous microbes and their human hosts at a
molecular-level resolution and defines host-interaction “fingerprints” for hundreds of
human-associated microbes. As expected, the BASEHIT atlas is sparse overall - most
bacterial strains bound fewer than five host proteins and most exoproteins failed to
interact with any of the bacterial strains in our collections. However, BASEHIT’s ability
to comprehensively test millions of potential bacteria:protein binding events revealed a
remarkable breadth and diversity of transkingdom interactions, which constitute a rich
but largely unexplored feature of host-microbiota connectivity.

Recent advances in metagenomics have clearly established that strain variation in the
microbiota can impact human disease outcomes. However, the identification of the key
distinctions between related strains that explain their differential impacts on host biology
remains a major challenge. BASEHIT offers an orthogonal and complementary method
to ascribe functions to individual microbial strains in a phylogenetically unbiased
manner, using host-exoproteome interactions as a “lens” to predict causal roles for
microbiota constituents in human health. This feature of BASEHIT may enable
functional classification of otherwise phylogenetically disparate microbes that exert a
common effect on the host by interacting with a shared set of host exoproteins.
Conversely, integration of interactome data with comparative genomics may also enable
the assignment of novel functions to large numbers of previously unannotated genes in
the human microbiome that are specialized for mediating direct interactions with the host.
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MATERIALS AND METHODS

Yeast Library
The yeast library design, construction, and characterization is described in Chapter 3.

BASEHIT screening.
Bacterial growth and labeling. Approximately 5 OD units of saturated bacterial culture
were pelleted and washed 3 times with 1 mL PBS. Washed bacteria were resuspended in
1 mL PBS with 5 µM Sulfo-NHS-LC-Biotin (Thermo Scientific) and incubated at 37° for
30 min. Excess unreacted biotinylation reagent was quenched by addition of 10 µL of 1M
Tris pH 8.0, and cells were washed with 1 mL PBS. Labeled cells were resuspended in 1
mL PBS with 10% (v/v) glycerol and frozen at -80°C for selections.

Yeast library selections. The yeast library was expanded in SDO-Ura at 30 °C. One day
later, yeast were induced by resuspension at an OD of 1 in SGO-Ura supplemented with
ten percent SDO-Ura and culturing at 30 °C for 24 hours. Prior to selection, plasmid
DNA was extracted from 400 µL of the pre-selection library to allow for comparison to
post-selection libraries using a Zymoprep Yeast cell Plasmid Miniprep II kit (Zymo
Research) by standard manufacturer protocols. 107 induced yeast cells were pelleted in
sterile 96-well v-bottom microtiter plate. Yeast cell were resuspended in 100 µL PBE, 10
µL of biotinylated bacteria were added, and the yeast were incubated with shaking for 2
hours at 4 °C. Yeast cells were washed once with 200 µL PBE, resuspended in 100 µL
PBE with a 1:100 dilution of streptavidin microparticles (Spherotech, 0.29 µm), and
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incubated with shaking for 1 hour at 4 °C. Yeast cells were washed once with 200 µL
PBE. Yeast cell were then pelleted and kept on ice. All following steps were carried out
at room temperature. Yeast cells were resuspended in 150 µL PBE. A custom 96-well
magnet was used to remove bead-bound yeast, which were washed twice with 150 µL
PBE by removal and subsequent re-application of the magnet. Washed yeast cells were
eluted into 150 µL PBE by removal of the magnet. Selected yeast were pelleted, and
expanded by growth in 1 mL SDO-Ura supplemented with chloramphenicol at 30 °C for
48 hours.

Next generation sequencing library preparation and sequencing. DNA was extracted
from yeast libraries using Zymoprep-96 Yeast Plasmid Miniprep kits or Zymoprep Yeast
Plasmid Miniprep II kits (Zymo Research) according to standard manufacturer protocols.
A first round of PCR was used to amplify a DNA sequence containing the protein display
barcode on the yeast plasmid. PCR reactions were conducted using 1 µL plasmid DNA,
159_DIF2 and 159_DIR2 primers, and the following PCR settings: 98 ⁰C denaturation,
58 ⁰C annealing, 72 ⁰C extension, 20 rounds of amplification. The PCR product was
directly used as template for the second round of PCR. A second round of PCR was
conducted using 1 µL PCR product, Nextera i5 and i7 dual-index library primers
(Illumina), and the following PCR settings: 98 ⁰C denaturation, 58 ⁰C annealing, 72 ⁰C
extension, 20 rounds of amplification. PCR products were pooled and run on a 2%
agarose gel. The band corresponding to 257 base pair was cut out and DNA (NGS
library) was extracted using a QIAquick Gel Extraction Kit (Qiagen) according to
standard manufacturer protocols. NGS library was sequenced using an Illumina MiSeq
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and Illumina v3 MiSeq Reagent Kits with 75 base pair single-end sequencing according
to standard manufacturer protocols.

Data analysis. Barcode counts were extracted from raw NGS data and analyzed using
custom codes. Enrichment calculations were performed using edgeR. Briefly, the
enrichments for all individual barcodes as well as the total abundance of each protein
(obtained as the sum of all barcode counts associated with that protein) were calculated
relative to the pre-selection library. The fraction of barcodes associated with a protein
with a positive enrichment (calculated log2FC >0) was multiplied by the overall
enrichment for that protein to provide a raw enrichment score. The raw enrichment score
was normalized by subtracting the raw enrichment scores of beads-only control selected
wells. All negative values were set to 0. Data generated from screens run on separate
days were processed separately until this step, to control for variation due to library drift.
Merged data across experiments were further processed to derive the BASEHIT score.
The merged, beads-corrected data were z-scored by protein. Proteins only detectably
enriched in one sample, failing to enrich above a raw enrichment score of 2 in any
sample, or with fewer than 5 barcodes associated, were penalized to avoid over-weighting
of low-enrichment samples. The final BASEHIT score was defined as the square-root of
the sum of the squares of the corrected z-score and the raw enrichment score, and
therefore reflects both the degree to which a protein was enriched by a particular
microbe, the internal replicates based on different barcodes associated with that protein,
and the specificity with which it was enriched.
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Validation experiments.
On-yeast binding confirmations. Individual proteins were recloned into the backbone
yeast-display vector as described for library construction, except no randomized barcode
fragment was included. Individual sequence-verified clones were transformed into
chemically competent yeast cells prepared with the Frozen-EZ Yeast Transformation II
Kit (Zymo Research) and grown in SDO-Ura. Yeast were induced for 24 hours in SGOUra and adequate surface display was confirmed by staining with 1:1000 anti-FLAG PE
antibody (BioLegend). Yeast cells (0.1 OD) were pelleted and resuspended in 100 µL
PBE. 10 µL of biotinylated bacteria prepared as described for screening were added, and
the yeast were incubated with shaking for 1 hour at 4°. The yeast were washed once with
100 µL PBE, resuspended in 100 µL PBE with 1:200 Streptavidin-PE (BioLegend), and
incubated with shaking for 30 minutes at 4°. The yeast were washed once with 100 µL
PBE, resuspended in 200 µL PBE, and analyzed on a Sony SA3800 spectral analyzer
(Sony Biotechnology). Binding to yeast displaying particular proteins was compared to
binding of yeast transformed with the empty yeast display vector.

Protein purification. Protein ectodomains were cloned into pCER243, a derivative of
pD2610-v2 (ATUM Bio). Protein ectodomains were cloned in-frame with an upstream
H7 leader sequence and downstream 3x(GGGGS) linker and hIgG1 Fc fragment with an
N297A mutation to abolish all effector functions. Expi293 cells (Thermo Fisher) were
transfected with the expression plasmids using ExpiFectamine 293 Transfection Kit by
manufacturer protocols (Thermo Fischer). Proteins were purified from clarified media 4
days post-transfection using magnetic Protein A beads (Lytic Solutions). Proteins were
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eluted with 100 mM glycine pH 3.0, and immediately neutralized with 1M Tris pH 8.0
and buffer exchanged into PBS. Protein purity was verified by SDS-PAGE. Protein
concentration was measured by absorbance at 280 nm. Proteins were snap-frozen in
liquid nitrogen and stored at -80°C until use.

Bacterial flow cytometry. Bacteria from saturated cultures (0.5-10 µL of culture volume)
were pelleted and resuspended in 50 µL PBE with recombinant protein (0.05-5 µM final
concentration of staining protein), and incubated with shaking for 1 hour at 4°C. Bacteria
were washed twice with 200 µL PBE, resuspended in 50 µL PBE with 1:100 anti-hIgGPE secondary antibody (BioLegend), and incubated with shaking for 30 minutes at 4°C.
Bacteria were washed once with 200 µL PBE, resuspended in 200 µL PBE, and analyzed
on a Sony SA3800 spectral analyzer (Sony Biotechnology). Binding of Fc-fusion proteins
was compared to binding of Fc alone. IL18BP was prepared as described previously, and
staining was identical except 1:100 anti-His-PE secondary antibody (BioLegend) was
used to detect protein binding.

Bacterial whole-cell ELISA. 1 OD of saturated bacterial culture was pelleted and washed
three times with PBS pH 7.0. The bacteria were resuspended in 1 mL PBS pH 7.0, and 110 µL of bacterial cell suspension was added to a flat-bottom Nunc MaxiSorp plate
(Thermo Scientific) and brought to a total volume of 100 µL in PBS pH 7.0. The plate
was sealed and incubated with shaking overnight at 4°. Pre-coated plates were washed
once with 250 µL wash buffer (PBS pH 7.0 with 0.05% Tween 20) and blocked with
shaking for three hours at room temperature in 150 µL blocking buffer (PBS with 1% w/v
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BSA). Blocked plates were washed three times with 100 µL wash buffer. Protein (0.0120 µg/mL final concentration of staining protein) was added in 100 µL total volume in
blocking buffer, and plates were incubated with shaking for two hours at room
temperature. Stained plates were washed three times with 100 µL wash buffer, and 100
µL of blocking buffer with 1:5000 goat anti-human IgG HRP (Millipore Sigma) was
added. Plates were incubated with shaking for 1 hour at room temperature. Plates were
washed three times with 100 µL wash buffer. 50 µL TMB substrate (BD Biosciences)
was added to the wells and plates were incubated for 15 minutes in the dark at room
temperature. 50 µL 2N sulfuric acid was added to the wells and absorbance at 450 nm
was measured in a Synergy HTX Multi-Mode Microplate Reader (BioTek).
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Fig. 4.1. BASEHIT identifies host-microbe interactions. (A) BASEHIT profiling enables
screening of hundreds of isolates representing a broad sample of the human microbiome
against the human exoproteome. BASEHIT results identify global patterns as well as
highlight individual bacterial activities. (B) Validation of the BASEHIT method using a
gold-standard host-microbe interaction. GFP labeled yeast displayed human IgG1-Fc
enriched following selection with biotinylated S. aureus cells. (C) and (D) Test selection
with the E. coli isolate strain MS21-1 prominently identifies binding to CD55 and
CEACAM1, the targets of the pathogenic Dr-family adhesin present in the MS21-1
genome, specifically in the Dr-family containing strain.
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Fig. 4.2. Identification of thousands of novel interactions between host proteins and
resident microbes. (A) Screening and validation pipeline to assess global breadth of hostmicrobe interactions. (B) Heatmap visualization of all possible binary interactions
between 477 screened strains and 2688 host proteins. (C) and (D) Orthogonal validations
of newly identified host-microbe interactions by flow cytometry (C) or ELISA (D).
Staining with indicated Fc-fusion proteins (red) is compared to Fc-control protein (black).
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Fig. 4.3. Host-microbe interaction patterns vary substantially across the collective human
microbiome. (A) tSNE dimensional reduction of all BASEHIT scores for all strains,
colored by phylum. (B) Four strains with variable levels of interaction are highlighted,
plotting the scores for all proteins.
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Fig. 4.4. Host-specific interactions vary across closely related strains of microbes. (A)
Bar plot of interactions with skin-expressed proteins across Staphylococcus isolates. Each
shaded region encompasses strains of individual species. Each column represents a single
strain, and the dotted line indicates the score cutoff of 5. (B) FAT2 staining of two S.
warneri isolates with different BASEHIT scores validates the strain variability in protein
binding. (C) Interactions of Fusobacterium strains isolated from multiple tissues with
immune proteins. The size and color of the circle indicates the score bin (<1, 1-5, or >5)
for each indicated strain to the individual proteins. (D) R. gnavus strain NWP327 binding
to all screened proteins. Proteins highly expressed on T cells are highlighted in blue, and
mucus-associated trefoil factors TFF1 and TFF2 are highlighted in pink. (E) Staining of
R. gnavus strains NWP327 (red), 325 (blue), and 326 (black) show strain-level variability
in CD7 binding. (F) Staining of R. gnavus NWP327 with increasing concentrations of
human or mouse CD7 protein showed species specificity in host receptor binding.

148

Chapter 5: A human secretome library screen reveals a role for Peptidoglycan
Recognition Protein 1 in Lyme borreliosis
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ABSTRACT

Lyme disease, the most common vector-borne illness in North America, is caused
by the spirochete Borrelia burgdorferi. Infection begins in the skin following a tick bite
and can spread to the hearts, joints, nervous system, and other organs. Diverse host
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responses influence the level of B. burgdorferi infection in mice and humans. Using a
systems biology approach, we examined potential molecular interactions between human
extracellular and secreted proteins and B. burgdorferi. A yeast display library expressing
1031 human extracellular proteins was probed against 36 isolates of B. burgdorferi sensu
lato. We found that human Peptidoglycan Recognition Protein 1 (PGLYRP1) interacted
with the vast majority of B. burgdorferi isolates. In subsequent experiments, we
demonstrated that recombinant PGLYRP1 interacts with purified B. burgdorferi
peptidoglycan and exhibits borreliacidal activity, suggesting that vertebrate hosts may use
PGLYRP1 to identify B. burgdorferi. We examined B. burgdorferi infection in mice
lacking PGLYRP1 and observed an increased spirochete burden in the heart and joints,
along with splenomegaly. Mice lacking PGLYRP1 also showed signs of immune
dysregulation, including lower serum IgG levels and higher levels of IFNγ, CXCL9, and
CXCL10.Taken together, our findings suggest that PGLYRP1 plays a role in the host’s
response to B. burgdorferi and further demonstrate the utility of expansive yeast display
screening in capturing biologically relevant interactions between spirochetes and their
hosts.

INTRODUCTION
Lyme disease is the most common tick-borne illness in North America. The
causative spirochete Borrelia burgdorferi is primarily transmitted by Ixodes scapularis
ticks [1]. The disease in humans often begins with a pathognomonic skin rash, erythema
migrans. Disseminated infection can lead to arthritis, carditis, and neurological
symptoms, among other clinical manifestations [2, 3].
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The pathogenesis of Lyme disease is multifactorial, involving both bacterial
components that influence virulence, dissemination and infectivity, and host factors that
are responsible for inflammation and the modulation of infection [4, 5]. The success of B.
burgdorferi as a pathogen can be attributed, in part, to its morphology. Its outer
membrane contains lipid raft-like microdomains that are associated with lipoproteins [6].
Some of the surface displayed lipoproteins are immunogenic and are involved in the
pathogenesis of Lyme disease. To evade host defenses and to interact with specific host
factors, B. burgdorferi alters the expression of various lipoproteins throughout its life
cycle [7, 8]. In addition, flagellin helps maintain the corkscrew-like shape of the
spirochete and facilitate movement [9]. B. burgdorferi also possesses an atypical
peptidoglycan (PG) in which the canonical lysine or meso-diaminopimelic acid residue at
the third position of stem peptides is replaced by ornithine [10, 11]. The PG meshwork
surrounds the cytoplasmic membrane and is composed of glycan strands cross-linked by
short peptides containing D- and L-amino acids [12]. In diderm bacteria, including B.
burgdorferi, the outer membrane shields the PG meshwork from the external
environment [13]. PG, including that of B. burgdorferi [11], can be recognized by host
pattern recognition receptors and stimulate immune responses [14]. The mammalian
immune response to B. burgdorferi involves both humoral and cell-mediated factors that
help to control or eliminate spirochetes [15-17]. There is a critical need to identify
specific host immune proteins that interact with spirochete components, including
lipoproteins, flagellar proteins, peptidoglycan and glycolipids.
Traditional approaches to identify potential interactions between host immune
proteins and B. burgdorferi ligands are slow and arduous, requiring overexpression of
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bacterial ligands and potential immune receptors in their native forms. It is imperative to
develop new methods of characterizing immune interactions with the spirochete in a
high-throughput manner. Systems biology approaches, such as yeast display technology,
enable simultaneous screening of large numbers of candidate host proteins. Yeast display,
in particular, enables facile expression of mammalian host proteins in their native
conformations at high surface densities that allow detection of even low-affinity
interactions [18]. In this study, we employed a recently developed technology termed
BASEHIT (BActerial Selection to Elucidate Host-microbe Interactions in high
Throughput) to simultaneously and comprehensively assess potential molecular-level
interactions between B. burgdorferi and thousands of human extracellular and secreted
proteins. Through this screen, we identify Peptidoglycan Recognition Protein 1
(PGLYRP1) as a key host protein that binds the atypical peptidoglycan of B. burgdorferi
and establishes that PGLYRP1 is required for optimal host responses against the
pathogen.

RESULTS
Identification of human host factors that interact with B. burgdorferi
We used a recently developed combinatorial screening technology termed
BASEHIT to identify specific human proteins that interact with B. burgdorferi and thus
may be involved in pathogenesis or protection. The principle of the BASEHIT assay
entails using intact, surface-biotinylated B. burgdorferi to pan a curated, geneticallybarcoded yeast-display library of >1,000 human extracellular and secreted proteins. Yeast
clones expressing bacterial-binding proteins are isolated by magnetic separation using
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streptavidin microbeads and are identified by next-generation sequencing of their specific
barcode sequences (Figure 5.1A). Because the expression of B. burgdorferi virulence
factors can vary with temperature, we performed BASEHIT with cultures grown at either
33°C or 37°C. Out of the more than 1000 proteins present in the library, only human
peptidoglycan recognition protein 1 (PGLYRP1) exceeded a stringent significance
threshold at both temperatures (Figure 5.1B). We expanded our screen to encompass a
wider range of Borrelia species and strains, again grown at both 33°C and 37°C,
including isolates from diverse geographic origins (Table S1). We observed that bacteria
from the genus Borrelia showed significantly greater binding to PGLYRP1 as compared
to hundreds of phylogenetically diverse non-Borrelia species (Figure 5.1C). PGLYRP1
was also found to bind to a small number of Gram-positive strains with scores above 3
only, but overall PGLYRP1 binding to Borrelia was stronger as compared to most Grampositive bacteria (Supplementary file S1 available on the PLOS Pathogens website). B.
burgdorferi N40 also exhibited additional predicted interactions with select human
extracellular and secreted proteins (Table S2).

PGLYRP1 binds and kills B. burgdorferi
To determine whether PGLYRP1 directly binds to B. burgdorferi N40, a
prototypic isolate commonly used in many laboratories, interaction studies were carried
out using sandwich ELISA. We observed a robust, dose-dependent interaction between
recombinant Fc-tagged human PGLYRP1 (0-100 ng) and whole cell B. burgdorferi lysate
(Figure 5.2A). A weak non-specific binding was observed with Fc domain alone, which
did not increase with concentration.
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To further validate the potential interaction between PGLYRP1 and B.
burgdorferi, we performed flow cytometry based binding assays. Since PGLYRP1 is
conserved in humans and mice with 67% identity (Figure S1), we tested whether mouse
PGLYRP1 also recognizes B. burgdorferi. Both murine and human PGLYRP1 bound to a
majority of B. burgdorferi cells at two different concentrations (10 and 40 µg/ml), while
secondary antibody alone showed weak reactivity to spirochetes. As a control, we used
recombinant CD55-His8 (40 µg/ml), a host immune protein that was predicted by the
yeast display screen to be unable to bind B. burgdorferi (Figure 5.1). As shown in Figures
5.2B and 5.2C, purified murine or human CD55-His8 did not recognize B. burgdorferi.
We also observed concentration-dependent binding of human and mouse PGLYRP1 to B.
burgdorferi (Figure S2), while secondary antibody alone showed only weak binding.
Collectively, these results confirmed the interaction between B. burgdorferi and both
human and murine PGLYRP1.
PGLYRP1 is known to be a bactericidal protein expressed by the myeloid cells,
primarily neutrophils [19, 20]. B. burgdorferi was incubated with purified human
PGLYRP1 for 48 hours in microaerophilic conditions at 33°C. The borreliacidal activity
of PGLYRP1 was assessed by BacTiter-Glo Microbial Cell Viability Assay, which has
been performed routinely for live Borrelia estimation [21-25]. We found that the purified
human PGLYRP1 shows borreliacidal activity in a concentration-dependent manner, as
shown in Figure S3. These results suggest that human PGLYRP1 can bind and kill
Borrelia in vitro.

Neutrophil mediated phagocytosis and killing of Borrelia
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Neutrophils kill bacteria in a variety of ways which include the release of granules
that contain many microbicidal enzymes [26]. We compared the neutrophils isolated from
mouse bone marrow of BALB/c wild type to BALB/c mice that lack an intact pglyrp1
gene (WT and PGLYRP1-/-). Neutrophils were incubated with fluorescent-dye (eFluor
670)-labeled B. burgdorferi at different ratios. The percent of neutrophils that
phagocytosed fluorescent Borrelia were analyzed by flow cytometry. Our data shows that
PGLYRP1 deficiency does not affect the ability of neutrophils to phagocytose B.
burgdorferi (Figure S4).
Further, the neutrophil mediated Borrelia killing assay showed that there was no
significant difference in the borreliacidal activity of neutrophils derived from BALB/c
WT and PGLYRP1 knockout mice (Figure S5). Based on our data, it is apparent that the
absence of PGLYRP1 does not affect the ability of neutrophils to kill Borrelia in vitro.

PGLYRP1 binds to B. burgdorferi peptidoglycan
PGLYRP1 has been shown to have a ligand-binding groove that is specific for
peptidoglycan [20]. We, therefore, confirmed the binding of PGLYRP1 with B.
burgdorferi PG. As shown in Figure 5.3A, a dose-dependent interaction was observed by
ELISA between purified PG and hPGLYRP1. Furthermore, flow cytometry-based
binding assays revealed that the binding between B. burgdorferi and human/murine
PGLYRP1-His8 was reduced with the addition of B. burgdorferi PG, indicating the
specificity of this interaction (Figures 5.3B and 5.3C).

PGLYRP1 influences murine Lyme borreliosis
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To assess the role of PGLYRP1 in the pathogenesis of Lyme borreliosis, we
compared the outcomes of B. burgdorferi infection of BALB/c WT and PGLYRP1-/mice. BALB/c mice can readily be infected with spirochetes, and while they do not
develop severe tenosynovitis like C3H mice, they are useful for the study of murine B.
burgdorferi infection [27]. The BALB/c WT and PGLYRP1-/- mice were infected with
1x106 spirochetes injected subcutaneously. Spirochete burdens in the heart and joint
tissues were assessed at 25 days post infection (dpi), and skin burdens were assessed by
ear punch biopsies at 14 and 25 dpi. There was no difference between the WT and
PGLYRP1-/- mice in the skin burden at either 14 or 25 dpi (Figures 5.4A and 5.4B).
However, the PGLYRP1-/- mice had a significantly higher spirochete burden in the hearts
and joints at 25 dpi (Figures 5.4C and 5.4D), suggesting a role for PGLYRP1 in
controlling B. burgdorferi dissemination during the systemic phase of infection.
Furthermore, B. burgdorferi infection induced modest splenomegaly in PGLYRP1-/- mice
compared to WT animals, which may represent activation and expansion of splenic
immune cells due to higher B. burgdorferi burden (Figure 5.4E).
Histopathological evaluation was performed to examine the development of acute
tenosynovitis in the mice. The ankle (tibiotarsal) joints from WT and PGLYRP1-/- mice
(N =3 uninfected controls per genotype and 25 infected mice per genotype) were
examined and assessed for the presence and severity of inflammation. Of the 6 uninfected
control mice tibiotarsal joints, only 1 joint (WT tibiotarsal) had trace inflammation (score
of 0.5). However, in the 50 tibiotarsal joints examined at 25 dpi, 44% of the tibiotarsal
joints from WT and 28% tibiotarsal joints from PGLYRP1-/- mice developed an
inflammatory response. Since BALB/c mice do not develop the frequency and severity of
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tenosynovitis found in C3H mice, we did not find any differences in tenosynovitis
severity of tibiotarsi (Figure 5.5A). These results suggest that, while the lack of pglyrp1
led to higher B. burgdorferi burden in animals, joint inflammation was not significantly
different.
The hearts from the 6 uninfected control and 50 infected mice 25 dpi described
above were examined for the presence and severity of inflammation [28, 29]. None of the
uninfected control mice were positive for carditis. However, in 50 mice examined at 25
dpi, 84% of the WT and 60% of PGLYRP1-/- infected mice demonstrated inflammation
in the heart. There were no significant differences in cardiac severity scores between the
groups (Figure 5.5B). Taken together with the tenosynovitis scores, these data
demonstrate that lack of pglryp1 does not significantly impact the severity of
inflammation of hearts and joints in BALB/c mice infected with B. burgdorferi.
To determine the effect of PGLYRP1 deletion on the B. burgdorferi specific
antibodies, we measured antibody responses to spirochete antigens via sandwich ELISA.
There was a significant reduction in B. burgdorferi-specific IgG in the sera obtained from
PGLYRP1-/- mice compared to WT BALB/c mice, collected at 25 dpi (Figure 5.6A),
while no differences were observed in B. burgdorferi-specific IgM levels at 25 dpi
(Figure S6).To determine the role of PGLYRP1 on class switching and concomitantly
antibody effector functions, we assessed B. burgdorferi specific IgG1, IgG2a, IgG2b and
IgG3 antibodies levels by ELISA. Similar to the overall IgG responses, the levels of B.
burgdorferi-specific IgG1, IgG2a, IgG2b and IgG3 were significantly lower in
PGLYRP1-/- infected mice than in WT BALB/c after 25 dpi (Figures 5.6B-E).
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Furthermore, serum cytokine profiles were assessed in both WT and PGLYRP1-/mice 25 dpi, using a mouse cytokine/chemokine array panel. Sera from uninfected WT
and PGLYRP1-/- mice were also probed as baseline controls. Increase in proinflammatory cytokines IFN-γ (Figure 5.7A), and related cytokines CXCL-9 (Figure
5.7B), CXCL-10 (Figure 5.7C) was observed in infected PGLYRP1-/- mice as compared
to parent WT BALB/c mice. The PGLYRP1-/- mice did not show significant differences
in other cytokine levels, including TNF-α, IL-10, IL-4, IL-5, IL-10, IL-17, CXCL-1,
MCP-1, MIP-1B, and MIP-2 levels compared to infected WT BALB/c mice (Figure S7).
These results show that the pglyrp1 absence in the mice increased the Th1 cytokine
response, while impairing murine antibody response to B. burgdorferi.

DISCUSSION

The pathogenesis of Lyme borreliosis is multifactorial and is associated with the
virulence of the pathogen and the host response to B. burgdorferi. This complex interplay
can influence the outcome of the infection and result in varying disease phenotypes [6].
Unbiased combinatorial approaches, such as BASEHIT, present an unparalleled
opportunity to identify key host factors that interact with B. burgdorferi. In this study, we
probed 53 different Borrelia isolates against 1,031 extracellular human proteins.
PGLYRP1 was identified as the most prominent candidate that interacts with multiple B.
burgdorferi isolates grown at 33°C and 37°C.
It has been reported that there are temperature-related changes in Borrelia gene
expression, which has been shown by different groups [30-32]; Several antigenic
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lipoproteins present on the Borrelia surface have been shown to be induced at 37°C, such
as OspC, BbK2.10, ElpA1, Erp proteins and P21 [30-34]. In BASEHIT, we found that
the PGLYRP1 interaction with Borrelia enhanced marginally at 37°C compared to 33°C.
This suggests that temperature-dependent changes in virulence-related gene expression in
Borrelia may enhance PGLYRP1 binding and may allow us to differentiate between
interactions happening at different stages of the spirochete life cycle.
PGLYRP1 is an innate recognition protein that binds to PG. Among the many
spirochete components that contribute to pathogenesis, it has recently been shown that B.
burgdorferi sheds PG during growth, and this activity may be associated with
inflammation during infection [11]. Using BASEHIT, we found that PGLYRP1 binds
more efficiently to B. burgdorferi spp., as compared to the other bacteria tested. This may
be due to the distinct morphology of B. burgdorferi or the unusual chemical composition
of PG [11, 35].
In line with this interpretation, we demonstrated direct binding of B. burgdorferi
to PGLYRP1, which could be reduced by supplementation with excess PG. This finding
intrigued us since B. burgdorferi is a diderm bacteria with an outer membrane and a layer
of peptidoglycan in the periplasmic space [36]. Peptidoglycan recognition proteins
(PGRPs) have been shown to directly bind to peptidoglycan in the bacterial cell wall in
Gram-positive bacteria [37]. In our screen, PGLYRP1 did recognize a small number of
Gram-positive bacteria. However, it is unclear why all of the Gram-positive bacteria
screened were not recognized. There may also be variation in peptidoglycan and
peptidoglycan-associated proteins across the Gram-positive bacteria used in this screen.

159

We think PGLYRP1 can bind to exposed peptidoglycan present on dividing
Borrelia as well as to damaged spirochete. Spirochetes also have unique peptidoglycan
which is continuously shedded and some of the shedded peptidoglycan may be loosely
associated with other antigens (Figure 5.8) [11]. The stronger binding of PGLYRP1 to
Borrelia could also be due to the unique ornithine within borrelial PG [11]. BASEHIT
screen indicates that PGLYRP1 may have a binding preference for unusually modified
peptidoglycan in Borrelia. It is also possible that PGLYRP1 may differentially recognize
cell-surface peptidoglycan (due to cross-linking with associated molecules in the cell
wall, etc), compared to free/soluble peptidoglycan, which is why PGLYRP1 only
interacted with a small number of Gram-positive bacterial strains while failed to bind
many Gram-positive strains tested. For Gram-negative bacteria, PGRPs have been shown
to bind uniformly with the outer membrane, which covers the thin layer of peptidoglycan
and is composed of lipopolysaccharide (LPS) [38]. In addition to PG, PGRPs bind LPS
and other components of the outer membrane using additional binding sites outside of the
peptidoglycan-binding groove [37, 39-44]. The ability of PGLYRP1 to bind B.
burgdorferi may be completely mediated by PG or involve additional lipoproteins on the
outer membrane, given the structural similarity to Gram-negative bacteria [45].
Variations in the surface lipoproteome may account for differences in efficiency scores
for PGLYRP1 interaction with the multiple Borrelia isolates in BASEHIT. These data
indicate that the PGLYRP1 may also bind to additional ligands present on the Borrelia
surface.
PGLYRP1 is involved in antimicrobial response and has been shown to kill
bacteria by inducing oxidative, thiol, and metal stress [46]. In Gram-positive bacteria,

160

PGRPs have direct interaction with PG, which allows for bacterial killing [38, 41].
PGRPs are able to induce a stress response in Gram-negative organisms by binding to the
outer membrane and activating a two-component system that involves a transmembrane
sensor and cytoplasmic regulator, leading to bacterial death [44, 47]. Our experiments
show that PGLYRP1 had direct bactericidal activity against Borrelia. The role of
PGLYRP1 in B. burgdorferi pathogenesis and dissemination is further corroborated by
higher load of B. burgdorferi in hearts and joints of mice lacking PGLYRP1. The
enhanced spirochete load in these tissues further substantiates our in vitro data that
PGLYRP1 can directly kill Borrelia. The alteration in immunoglobulin responses against
B. burgdorferi, observed in PGLYRP1-/- mice also suggests a role for this protein in
adaptive immune responses. This may also be partially responsible for higher heart and
joint burden, as antibody responses help combat B. burgdorferi infection [48, 49].
B. burgdorferi exhibits a tropism for heart and joint tissues during murine
infection, which are the main sites of inflammation. In many cases, an increase in the B.
burgdorferi burden in mice is associated with increased severity of disease [50, 51]. In
our study, PGLYRP1 deficiency in BALB/c mice did not result in differences in carditis
and tenosynovitis severity, despite a higher pathogen load. This finding is consistent with
some studies where disease severity and spirochete numbers do not necessarily correlate
[51, 52]. Further studies in different strains of inbred mice including animals that develop
both severe and mild tenosynovitis, as well as experiments involving different doses and
isolates of B. burgdorferi will be needed to fully elucidate the influence of PGLRYP1 on
Borrelia pathogenesis.
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PGLYRP1 has been shown to modulate inflammation in multiple murine models
for experimental colitis, asthma, and contact dermatitis [19, 53, 54]. In addition,
PGLYRP1 can complex with bacterial PG as a ligand for TREM-1 (Trigger receptor
expressed on myeloid cells), a pro-inflammatory receptor implicated in innate immune
activation [55]. In our study, PGLYRP1-/- mice exhibited a differential cytokine profile
with notable increases in serum IFN-y, CXCL-9, and CXCL-10 levels, favoring a Th1
immune response. The downstream effects of these elevated pro-inflammatory markers
remain unclear, as it may be a consequence of higher pathogen burden or directly related
to the absence of PGLYRP1. These studies suggest an immunomodulatory role of
PGLYRP1; however, further work is warranted to understand these mechanisms in Lyme
disease pathogenesis.
In conclusion, we identified novel human immune proteins that bind B.
burgdorferi through an unbiased systems proteomics screen (BASEHIT). Our results
show that BASEHIT may be very selective and only identified a small number of
immunogenic proteins that could potentially interact with Borrelia. However, it is
possible that Borrelia adhesins may not be accessible enough to be detected or their
expression level is too low for the Borrelia isolates used in the assay
To our knowledge, this novel method is the only approach to screen a large
number of pathogens and identity interacting partners from a library of more than 1000
human secretory proteins in a simple and efficient manner and will provide a new
benchmark in identifying host-pathogen interactions against Borrelia. In particular, we
uncovered a novel interaction between PGLYRP1 and B. burgdorferi. We confirmed this
interaction using orthogonal methods and identified a role for PGLYRP1 in controlling B.
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burgdorferi burden during murine infection. This revealed a new aspect of B.
burgdorferi- host interactions, where PGLYRP1 binds to Borrelia cells and kills the
rapidly dividing spirochete. B. burgdorferi, in turn, may be able to subvert this attack by
shedding muropeptides that neutralize PGLYRP1 during dissemination to other tissues.
PGLYRP1 not only controls Borrelia growth through direct interactions, but also
indirectly by enhancing effective antibody responses. The role of PGLYRP1 in the
humoral response could be due to its involvement in inflammatory signaling and
maintaining a balance between Th1/Th2 responses, which may also affect pathogenesis.
Further applications of BASEHIT may enable the identification of additional host factors
involved in pathogenic processes caused by Borrelia and other bacterial species.

MATERIALS AND METHODS

Ethics Statement: All experiments performed in this study were conducted in
accordance with the Guide for the Care and Use of Laboratory Animals. Protocols were
approved by the Institutional Animal Care and Use Committee at Yale University
(Protocol Permit Number: 07941). All efforts were made to reduce animal suffering
during this study.

Borrelia culture: For screening, 53 isolates of several Borrelia species were grown at
33°C and 37°C in Barbour-Stoenner-Kelly H (BSK-H) complete medium (SigmaAldrich, #B8291) with 6% rabbit serum. The live cell density was ~106-107 cells/mL as
determined by dark field microscopy and hemocytometric analysis. The species included
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various isolates of relapsing fever spirochetes and Borrelia burgdorferi sensu lato
complex, such as, B. miyamotoi, B. anserina, B. crocidurae, B. duttonii, B. hispanica, B.
persica, B. burgdorferi sensu stricto, B. mayonii, B. carolinensis, B. americana, B.
kurtenbachii, and B. afzelii (S1 Table). Spirochetes were washed twice with PBS,
resuspended in PBS containing 5 µM Sulfo-NHS-LC-Biotin (BioVision, #2326-50),
incubated at 37°C for 30 min, washed again with PBS, and glycerol stocks (10% v/v in
PBS) were made for future use in yeast display screening assays. A low passage (P<5)
clonal isolate of B. burgdorferi N40 grown at 33°C in complete BSK-H medium was
used throughout the study.

Yeast library screening: Details of library construction and selections are described in
Chapters 3 and 4, although the precise composition of the yeast library and scoring
system are variations on those previously described. Briefly, a library of barcoded
plasmids containing the extracellular portions of 1031 human proteins was expressed in
Saccharomyces cerevisiae strain JAR300 and maintained in SDO-Ura (Synthetic dropout media, US Biological #D9535 prepared with 20 g/L glucose, according to
manufacturer's instructions). Expression of surface protein display was induced by
culturing the library in media containing 90% galactose and 10% glucose for 24 hours at
30°C. 1x107 Induced yeast cells were harvested in a sterile 96-well v-bottom microtiter
plate. Yeast cells were resuspended in 100 µL PBE (PBS + 0.5% w/v BSA + 0.5 mM
EDTA) with 10 µL of biotinylated bacteria added and incubated for 1 hour at 4°C with
shaking. Yeast cells were washed once with 200 µL PBE, resuspended in 100 µL PBE
containing 1 µL of streptavidin microparticles (Spherotech, 0.29 µm, #SVM-025-5H) and
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incubated for 1 hour at 4°C with shaking. Yeast were washed once with 200 µL PBE and
bead bound cells were selected by magnetic separation and subsequently expanded in 1
mL SDO-Ura supplemented with chloramphenicol at 30°C. DNA was extracted from
selected yeast cell libraries using Zymoprep-96 Yeast cell Plasmid Miniprep kits or
Zymoprep Yeast cell Plasmid Miniprep II kits (Zymo Research) according to standard
manufacturer protocols. DNA was amplified with custom primers and sequenced using
an Illumina MiSeq and Illumina v2 MiSeq Reagent Kits according to standard
manufacturer protocols. Barcode counts were extracted from raw NGS data using Python.
All enrichment calculations were performed using edgeR [56]. The score for each
gene is defined as the overall enrichment for that gene (relative to the unselected library)
multiplied by the percentage of barcodes associated with the gene that enriched (defined
as logFC >0). Since a negative log fold change means a protein was depleted, so for
simplicity, all negative values are set to zero.

Enzyme-linked immunosorbent assay (ELISA) for analysis of B. burgdorferi
interaction with human PGLYRP1: Spirochetes were grown to the density of ~107
cells/mL and harvested at 5000 x g for 15 minutes. Cells were washed twice with PBST
(PBS containing 0.05% Tween-20), pelleted and lysed using Bug-buster Protein
Extraction Reagent (Novagen, #70921-3), as previously described [57]. Protein
concentration in the lysate was measured by absorbance at 280 nm. In a 96-well plate,
wells were coated with 100ng of B. burgdorferi lysate. Samples were blocked with 1%
BSA followed by incubation with either recombinant human PGLYRP1 conjugated with
an Fc tag or a control protein fused with an Fc tag at varying concentrations (1 ng-100
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ng) for 1 hour at 37°C. After washing and incubating with Goat anti-human IgG HRP
conjugated secondary antibody (Sigma-Aldrich, #AP309P) (1:5000), KPL Sureblue TMB
Microwell Peroxidase substrate, 1-component (Seracare, #5120-0077) was added. The
reaction was stopped with 2 M sulfuric acid, and absorbance was read at 450 nm.

Human PGLYRP1 binding to B. burgdorferi PG: PG was purified as previously
described [10, 11, 58]. Then, 96-well flat-bottom microplates were coated overnight at
room temperature with poly-L-lysine solution (0.1% w/v). Wells were washed twice with
PBST and 100 µL of intact PG sacculi (1µg/mL in PBS) isolated from B. burgdorferi
B31 MI was added to duplicate wells, with PBS alone as a negative control. After
overnight incubation at 4°C, wells were washed twice with PBST and blocked with PBS
containing 3% BSA. After washing, recombinant human PGLYRP1 (R&D Systems,
#2590-PGB) was added to each well at a concentration of 500 ng/mL in PBS containing
1% BSA. After incubating for 2 hours at 30°C, wells were washed with PBST and 100
µL 6X-His Tag polyclonal antibody, HRP (Invitrogen, #MA1-135-A488) was added at
1:20,000 dilution. Plates were incubated for 1 hour at room temperature with shaking,
followed by washing with PBST and adding 1-Step Ultra TMB-ELISA Substrate
Solution (Seracare, #52-00-03). After allowing color development to proceed for 10
minutes, reactions were stopped by addition of 2 M sulfuric acid and the absorbance was
measured at 450 nm.

Borreliacidal assay: The BacTiter Glo microbial cell viability assay provides a method
for determining the number of viable microbial cells in culture based on quantitation of
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the ATP present by measuring luminescence. The luminescent signal is proportional to
the amount of ATP present, which is directly proportional to the number of viable cells in
culture [21-25]. To test the borreliacidal activity of human PGLYRP1-His8 (0-66.7
ng/µl), we incubated the protein with 1x105 spirochetes in microaerophilic conditions at
33°C for 48 h in a final volume of 300 μL, and calculated the percent viable spirochetes
using BacTiter-Glo (Promega) as described previously [21-25].

Flow cytometry based PGLYRP1 and PG binding assay: Low passage B. burgdorferi
were cultured to a density of ~106-107 cells/mL, washed two times with PBS and
incubated with either recombinant human PGLYRP1 (with 8X-His tag), recombinant
mouse PGLYRP1 (with 6X-His tag) (Sino Biological, #50115-M08H), recombinant
human CD55 (with 8X-His tag), or murine CD55 (with 8X-His tag) at room temperature
for 1 hour. Varying concentrations of purified B. burgdorferi PG [11] were used for this
assay. PG preparation had been sonicated prior to use and consisted of fragmented
sacculi. Borrelia PG was pre-incubated with either murine or human PGLYRP1 and was
subsequently added to Borrelia to test for binding. After a co-incubation period of 1 hour,
spirochetes were fixed in 4% PFA, washed three times with PBS and blocked in 1% BSA
overnight at 4°C. The spirochetes were probed anti 6X-His monoclonal antibodyconjugated to Alexa Fluor 488 (ThermoFisher, #MA1-21315-488) and run through
SA3800 Spectral Analyzer (Sony Biotechnology). The data was analyzed by FlowJo.

In vivo infection of mice: Pathogen-free BALB/c mice wild-type (WT) (Jackson
Laboratory) and BALB/c: Pglyrp1tm1Rdz/Pglyrp1tm1Rdz (PGLYRP1-/-) knockout mice [53,
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59], 6 to 8 weeks of age were infected with low passage B. burgdorferi (1x106
spirochetes subcutaneously, 7-9 mice/group). Uninfected WT and PGLYRP1-/- BALB/c
mice were used as controls. Ear punches were taken at 14- and 25-days post-infection to
compare the Borrelia burden in the skin. At 25 days post infection (dpi), heart and joint
tissue punches were also collected to quantify the spirochete levels. The spleen weights
were measured to assess splenomegaly. The protocol for the use of mice was reviewed
and approved by the Yale Animal Care and Use Committee.

Phagocytosis assay: Bone marrow cells from BALB/c WT and PGLYRP1-/- mice were
harvested and neutrophils were separated using density gradient centrifugation [60]. B.
burgdorferi were labeled with eBioscience Cell Proliferation Dye eFluor 670
(ThermoFisher, #65-0840-85 which binds to any cellular protein containing primary
amines, and the spirochetes were washed multiple times to remove excess dye.
Neutrophils were kept in RPMI1640 culture medium, supplemented with 10% (vol/vol)
fetal bovine serum. Neutrophils and spirochetes were mixed in different ratios from 1:1 to
1:30. The suspensions were incubated for 60 minutes at 37°C in the presence of 5% CO2
in 96-well U-bottom plate. After incubation, the suspensions were centrifuged at 500x g
for 10 min. The pellets were washed twice with PBS, fixed in 2% PFA, and kept at 4°C
until further processing. The cells were run through LSRII flow cytometer and analyzed
by FlowJo software. Neutrophils were gated based on forward and side scatter, and
Borrelia phagocytosing cells were identified by fluorescence detected with a 660/20 band
pass filter in APC channel. The data is represented as % of neutrophils positive for eFluor
670.
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Neutrophil killing assay: Bone marrow cells from BALB/c WT and PGLYRP1-/- mice
were harvested and neutrophils were separated using density gradient centrifugation [60].
Neutrophils were kept in DMEM culture medium, supplemented with 10% (vol/vol) fetal
bovine serum. Neutrophils and B. burgdorferi (1X105) were mixed in the ratio of 1:1 in
the absence or the presence of mouse serum (10%). The suspensions were incubated for
60 minutes at 37°C in the presence of 5% CO2 in a 96-well flat-bottom plate in 50 µL.
After incubation, 250 µL BSK-H media was added to the suspensions and kept at 33°C
for 72 hours. The Borrelia numbers were counted in Neubauer chamber under the
microscope. The experiment was performed three times in triplicates.

Quantification of Borrelia burden: DNA was extracted from heart, joint, and ear punch
samples using Qiagen DNeasy Blood & Tissue Kit, Qiagen. Quantitative PCR was
performed using iQ-SYBR Green Supermix (Bio-Rad). For quantitative detection of B.
burgdorferi burden within mouse tissue samples, q-PCR was performed with DNA using
flagellin (flaB), a marker gene for Borrelia detection. The mouse β-actin gene was used
to normalize the amount of DNA in each sample. The nucleotide sequences of various
primers used in specific PCR applications are indicated in Table S3.

Antibody titers against B. burgdorferi: IgG and IgM titers against B. burgdorferi were
detected in mouse sera by ELISA, as described above. Briefly, wells were coated with
lysate of B. burgdorferi, blocked, and incubated with mouse sera diluted in 1% BSA at
varying titers (1:200, 1:2000, 1:20,000, 1:200,000). After washing, Goat anti-mouse IgM
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HRP conjugated antibody (1:10,000, ThermoFisher #62-6840) or Rabbit anti-mouse IgG
HRP conjugated antibody (1:10,000, ThermoFisher, #61-6520) or Goat anti-mouse
IgG1/IgG2a/IgG2b/IgG3 HRP (1:10,000, Abcam, ab97240, ab97241, ab97250, ab97260)
antibody was added. KPL Sureblue TMB Microwell Peroxidase substrate, 1-component
was added, and the reaction was stopped with 2 M sulfuric acid. The absorbance of wells
was read at 450 nm.

Cytokine profile: Serum collected from each group of mice was sent for cytokine
analysis by the Mouse Cytokine/Chemokine Array 31-plex (MD-31) performed by Eve
Technologies. The cytokines represented by this array are Eotaxin, G-CSF, GM-CSF,
IFN-γ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p40), IL-12
(p70), IL-13, IL-15, IL-17A, IP-10, KC, LIF, LIX, MCP-1, M-CSF, MIG, MIP-1α, MIP1β, MIP-2, RANTES, TNFα, and VEGF.

Heart and joint histopathology analysis: Mice were euthanized by CO2 asphyxiation
and the heart and one rear leg from each mouse were immersion-fixed in 10% neutral
buffered formalin (NBF) (hearts) and Bouin’s (Ricca Chemical Corp.) or 10% solution
NBF followed by Decal Solution (rear leg). Hearts were bisected and then tissues were
processed, embedded, sectioned and stained with hematoxylin and eosin (HE) by routine
methods (Comparative Pathology Research Core in the Department of Comparative
Medicine, Yale School of Medicine). The tibiotarsi were scored in a blinded fashion for
tenosynovitis severity using the 3 point Barthold scoring system: 0 (negative), 1
(minimal), 2 (moderate), to 3 (severe), by an experienced veterinarian (CJB) (trained in
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veterinary pathology, as previously described [29, 61]. The hearts were also scored in a
blinded fashion for carditis severity on the Booth 5 point scale system of 0 (negative), 1
(minimal), 2 (mild), 3 (moderate), 4 (marked) to 5 (severe), as previously described [29].

Gene cloning and expression: Human PGLYRP1 (amino acids 22-196) or CD55
(human amino acids 35-353 or mouse amino acids 35-362) was cloned into pEZT-Dlux, a
modified pEZT-BM vector. Modifications included insertion of an H7 Leader Sequence
followed by an AviTag (Avidity), HRV 3C site, protein C epitope, and an 8X His tag.
Modified pEZT-BM vector was a kind gift from Ryan Hibbs (Addgene plasmid #74099).
Expi293 cells (ThermoFisher, #A14527) were transfected with the PGLYRP1 or CD55
expression plasmid using ExpiFectamine 293 Transfection Kit (ThermoFisher, #
A14524). Protein was purified from clarified media by nickel-nitrilotriacetic acid
chromatography and desalted into PBS. For Fc-tagged proteins, human PGLYRP1
(amino acids 22-196) was cloned into pD2610-v1 (ATUM Bio) as an N-terminal fusion
to the Fc fragment of human IgG1, with an N297A mutation to eliminate all effector
functions, and a 3X (GGGGS) linker sequence. Expi293 cells (Thermo Fisher) were
transfected with the PGLYRP1 or control Fc expression plasmid (containing the Fc
fragment and linker sequence) using ExpiFectamine 293 Transfection Kit (Thermo
Fisher). Protein was purified from the supernatant 96 hours post-transfection using
Protein A sepharose (Gold Biotechnology). The column was washed with PBS and eluted
using 100 mM glycine pH 3.0. Eluted protein was immediately neutralized with 1 M Tris
pH 8.0 and desalted into PBS. Protein purity was verified by SDS-PAGE. Protein
concentration was measured by absorbance at 280 nm.
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Statistical analysis: The analysis of all data was performed by Student’s t-test, MannWhitney, or ANOVA in Prism 8.0 software (GraphPad Software, Inc., San Diego, CA).
A p-value of <0.05 was considered statistically significant.
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Figure 5.1. Screening with Yeast-display library. (A) Schematic of yeast-display
screen- A library of yeast cells, each displaying a single human protein encoded by a
uniquely bar-coded plasmid was pooled and mixed with surface biotinylated Borrelia.
The BASEHIT library was scaled to 96-well magnetic separation format for this screen.
Magnetic separation using streptavidin microbeads, followed by next-generation
sequencing was used to identify yeast displaying proteins that bind to the bacterial cells.
Plasmid DNA was isolated and sequenced to identify the proteins (B) Host Interactions
with B. burgdorferi N40- spirochete from the cultures grown at 33°C or 37°C were
surface biotinylated and used for yeast selections, as described above. The data shows
average scores of four independent runs of the selection on the 33°C grown sample and
one run on the 37°C grown sample. The scores were normalized for diverse microbes (i.e.
Escherichia coli, Staphylococcus aureus, Bacillus subtilis, Shigella flexneri, and
Bifidobacterium adolescentis) as background correction for non-specific binding activity.
(C) PGLYRP1 interaction with Borrelia species- Samples from 53 Borrelia isolates,
grown at two different temperatures (when possible), were screened against the host
protein library as described above for B. burgdorferi, as were 370 additional bacterial
samples. The score for each gene is defined as the overall enrichment for that gene
(relative to the unselected library) multiplied by the percentage of barcodes associated
with the gene that enriched (defined as logFC >0). The calculated scores of Borrelia
species were compared with those of the other bacteria. The bars represent mean ± SD
and p-values reflect a Mann-Whitney U-te

184

Figure 2
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Figure 5.2. Binding of PGLYRP1 with B. burgdorferi. (A) ELISA results show the
interaction of human PGLYRP1 with lysate of B. burgdorferi. The lysate was
immobilized on microtiter wells and probed with increasing concentrations of either
recombinant human PGLYRP1-Fc protein (1-100 ng, red bars) or Fc control protein
(gray bars). The values plotted represent the mean ± SEM of three replicates from a
single experiment. p-value is displayed in the graph and reflects a student t-test. (B and
C) Binding of human (B) and mouse (C) PGLYRP1 to B. burgdorferi. The culture was
grown to a density of 106 CFU/mL and incubated with varying concentrations of
recombinant PGLYRP1-His8 (10 µg/mL in green, 40 µg/ml in red). B. burgdorferi bound
to recombinant PGLYRP1-His8 was measured using a secondary AF488-His6 monoclonal
antibody by flow cytometry. Overlay histograms show protein binding to B. burgdorferi
identified by Alexa Fluor 488, His6 monoclonal antibody. Binding of recombinant
human/murine CD55-His8 (40 µg/ml in blue) to B. burgdorferi was used as control. The
background binding of AF488-His6 alone with B. burgdorferi is shown in gray shaded
region. Results from one independent experiment are shown here. For (B) and (C), the Yaxis represents relative cell counts calculated as a percentage of the maximum events
(Borrelia).
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Figure 5.3. PGLYRP1 shows competitive binding to purified peptidoglycan and B.
burgdorferi. (A) ELISA shows the binding of recombinant human PGLYRP1 at two
concentrations, 100 and500 ng/ml to peptidoglycan (PG) sacculi isolated from B.
burgdorferi (Bb) as compared to a PBS negative control. The values plotted represent the
mean ± SEM of two technical replicates from a single experiment. (B and C) Flow
cytometry-based experiment showing binding of human (B) and mouse (C) PGLYRP1 to
B. burgdorferi, after pre-incubating the protein in the absence (red) and presence (blue)
of B. burgdorferi PG. Recombinant PGLYRP1-His6 (1 µg/mL) was pre-incubated with
Borrelia PG (10 µg/mL) and then added to live B. burgdorferi overlay histograms show
PGLYRP1 binding to B. burgdorferi identified by Alexa Fluor 488, His6 monoclonal
antibody. Results from one independent experiment are shown here. For (B) and (C), the
Y-axis represents relative cell counts calculated as a percentage of the maximum events
(Borrelia).
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Figure 5.4. Comparison of Borrelia burden in WT BALB/c and PGLYRP1-/knockout mice. Wild-type BALB/c and PGLYRP1-/- mice (at least n=7 in each group)
were infected with 1x106 spirochetes by subcutaneous injection. (A and B) Skin B.
burgdorferi burden was assessed by ear punch biopsies at 14 d (A) and 25 d (B) post
infection, by qPCR for Borrelia specific gene (flaB) normalized to mouse β-actin. (C and
D) B. burgdorferi burden was assessed in hearts (C) and joints (D) at day 25, by qPCR as
above. Results from two independent experiments are shown. Each data point represents
the value of an individual animal. (E) The extent of splenomegaly was expressed as
spleen weights in WT and PGLYRP1-/- mice infected with B. burgdorferi at day 25.
Results from one independent experiment are shown here. Each data point represents the
value of an individual animal. The bars represent mean ± SEM and p values reflect
student t-test.
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Figure 5.5. Comparison of tenosynovitis and carditis severity after infection between
WT BALB/c and PGLYRP1-/- knockout mice. (A) Histopathology scores from
tibiotarsi for individual mice in infected wild-type mice (WT Inf) and infected
PGLYRP1-/- mice (PGLYRP1-/- Inf) at 25 days post infection. Tibiotarsi were scored by
blinded examination for tenosynovitis on a scale of 0 (negative) to 3 (severe). (B) The
severity of cardiac inflammation in the heart of infected WT and PGLYRP1-/- mice 25 d
post infection. Hearts were scored in a blinded fashion for carditis on a scale of 0
(negative) to 5 (severe). Similar to tenosynovitis scores, PGLYRP1-/- infected mice
demonstrated no significant difference in carditis scores compared to WT mice. Results
from at least two independent experiments (at least n=7 in each group) are pooled and
shown here. The bars represent mean ± SEM and p values reflect Mann-Whitney U-test.
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Figure 5.6. Difference in antibody level after B. burgdorferi infection in mice.
Antibody levels in uninfected wild type BALB/c (WT) and PGLYRP1-/- mice were
compared with those in the infected ones (at least n=7 in each group). Representative
results from one independent experiment are shown. (A) Whole cell lysate of B.
burgdorferi was coated on microtiter plate and serum from either uninfected WT,
infected WT, uninfected PGLYRP1-/- or infected PGLYRP1-/- mice was used at varying
dilutions. The binding was measured by secondary goat anti-mouse IgG HRP-conjugated
antibody. Statistically significant increase in binding was observed at IgG titers 1:200,
1:2000, 1:20000 in infected WT compared to infected knockout mice. (B-E) Levels of
different IgG isotypes (IgG1, B; IgG2a, C; IgG2b, D; IgG3, E) were measured against B.
burgdorferi lysate, using mouse serum at varying dilutions. The binding was measured by
secondary goat anti-mouse IgG1, IgG2a, IgG2b or IgG3 HRP-conjugated antibody.
Statistically significant increase was observed in IgG1, IgG2a, IgG3, and IgG2b at 1:200
and 1:2000 dilution in infected WT compared to infected PGLYRP1-/- mice.
Representative results from one independent experiment are shown. Each data point
represents an individual animal in the corresponding group. The bars represent mean ±
SEM and p values reflect student t test.
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Figure 5.7. Differential cytokine profile after infection with B. burgdorferi in mice.
Serum cytokine profile was assessed in both wild-type and PGLYRP1-/- mice 25 d postinfection ((at least n=7 in each group) using a mouse cytokine/chemokine 31-plex (MD31) array. An increase in pro-inflammatory cytokines IFN-γ (A) and related cytokinesCXCL-9 (B) and CXCL-10 (C) was observed in infected PGLYRP1-/- mice as compared
to parent BALB/c mice. Representative results from one independent experiment are
shown. Each data point represents an individual animal in the corresponding group. The
bars represent mean ± SEM and p-values reflect student t-test.
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Figure 8

Figure 5.8: Schematic showing Borrelia membrane architecture and PGLYRP1
binding. B. burgdorferi is a diderm bacteria where the outer membrane surrounds the
peptidoglycan layer and protects it from the external environment. The peptidoglycan
meshwork, in turn, surrounds the cytoplasm. Our results suggest PGLYRP1 binds to
Borrelia peptidoglycan.
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A human secretome library screen reveals a role for Peptidoglycan Recognition Protein 1
in Lyme borreliosis

SUPPORTING INFORMATION

Figure S1. Multiple sequence alignment of human and mouse PGLYRP1.

Figure S2. Concentration-dependent binding of human PGLYRP1 to B. burgdorferi.
Spirochetes from B. burgdorferi culture were incubated with increasing concentrations of (A)
recombinant human PGLYRP1-His8, and (B) recombinant mouse PGLYRP1-His6, at
concentrations 0.01 µg/mL, 0.1 µg/mL and 1 µg/ml. Representative results from one
independent experiment are shown. Each data point represents an individual animal in the
corresponding group. Data is expressed as the percentage of spirochetes that were shown to
bind. The Y-axis represents relative cell counts calculated as percentage of the maximum
events (Borrelia).

Figure S3. PGLYRP1 dependent killing of B. burgdorferi. Human PGLYRP1- His8 (0-66.7
ng/µl) was incubated with B. burgdorferi (1x105) for 48 hours in 96-well plate, keeping final
volume 300 µl. The viability was assessed by BacTiter Glo assay. The graph shows effect of
human PGLYRP1 concentration on Borrelia (BbN40). Results from one independent experiment
performed in triplicates are shown here.

Figure S4. In vitro phagocytosis assay using neutrophils from wild type (WT) and
PGLYRP1-/- mice. The neutrophils isolated from mouse bone marrow were incubated with
eFluor 670 dye-labeled B. burgdorferi at different ratios for 1 hour. The neutrophils were
subsequently washed and analyzed by flow cytometer. (A) Histogram showing neutrophils that
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phagocytosed Borrelia. High and low represent the ratio of 30 and 1 (B. burgdorferi, 1x105). Yaxis represents relative cell counts calculated as percentage of the maximum events (Borrelia).
(B) The graph show percent of phagocytic neutrophils plotted against Borrelia numbers. Results
from three independent experiments are shown. The bars represent mean ± SEM and p-values
reflect Student t-test.

Figure S5. Comparison of Borrelia killing using neutrophils from WT and PGLYRP1-/mice: Neutrophils isolated from mouse bone marrow were incubated with 1x105 B. burgdorferi
for 1 hour in DMEM media in the absence (A) or presence of 10% mouse serum (B). The assay
was performed in 96-well flat-bottom plates and volume was 50 µl. After 1 hour, 250 µl of BSKH medium was added to the wells. The plates were incubated in microaerophilic conditions at
33°C for 72 hours. The Borrelia numbers were counted in Neubauer chamber under the darkfield microscope. The Y-axis represents B. burgdorferi numbers (in 2.5 x 106). The experiment
was performed in triplicates and results from one independent experiment are shown. The bars
represent mean ± SEM and p-values reflect the Mann-Whitney test.

Figure S6. B. burgdorferi specific IgM titers in mice. Antibody levels in uninfected wild type
BALB/c (WT) and PGLYRP1-/- mice were compared with those in the infected ones (at least n=7
in each group). A representative result from one independent experiment is shown. Whole-cell
lysate of B. burgdorferi was coated on a microtiter plate and serum from either uninfected WT,
infected WT, uninfected PGLYRP1-/- or infected PGLYRP1-/- mice was used at 1:200 dilution.
The binding was measured by the secondary Goat anti-mouse IgM HRP-conjugated antibody.
No significant difference in IgM level was observed in infected WT compared to infected
PGLYRP1 knockout mice. Each data point represents an individual animal in the corresponding
group. The bars represent mean ± SEM and p-values reflect student t-test.
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Figure S7. Cytokine response in WT and PGLYRP1-/- mice. The infected PGLYRP1-/- mice
also showed overall different levels (in pg/mL) of CXCL-1, MCP-1, MIP-1B, and MIP-2 (A) and
TNF-α, IL-10, IL-4, IL-5, IL-10, IL-17 (B) as compared to BALB/c mice infected mice although
the profiles were statistically insignificant. Representative results from one independent
experiment are shown. Each data point represents an individual animal in the corresponding
group. The bars represent mean ± SEM.
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Table S1. Borrelia species & number of corresponding isolates screened.
Species
Borrelia burgdorferi sensu lato complex
B. afzelii
B. Americana
B. burgdorferi sensu stricto
B. carolinensis
B. garinii
B. kurtenbachii
B. mayonii
Borrelia sp.

Number of Isolates Screened
39
13
1
9
3
3
1
1
8

Relapsing fever spirochetes
B. anserina
B. crocidurae
B. duttonii
B. hispanica
B. miyamotoi
B. persica

17
1
1
1
1
12
1

Table S2. Top hits from yeast display screen for B. burgdorferi N40 in order of descending
enrichment scores

Protein

Function with Panther family annotation

PGLYRP1

peptidoglycan immune receptor activity
inhibitory receptor present on mononuclear
leukocytes
synapse organization
mannose, phospholipase, lectin receptor
related pthr22803
vascular endothelial growth factor-activated
receptor activity
tyrosine-protein kinase receptor pthr24416
MyD88-independent toll-like receptor
signaling pathway
melanocyte protein pmel 17-related
pthr11861
glycoprotein ib beta pthr22650
pro-inflammatory cytokine that act on
monocytes and macrophages to secrete
inflammatory cytokines

LAIR2
LRRTM2
REG4
NRP2
TYRO3
TLR3
TMEM130
GP1BB
IL32

196

B. burgdorferi
33°C score average
bacterial score
4.029706862

p-value relative
to average
bacteria score
2.65251E-05

2.49646777

0.015449324

1.512091167

0.292351992

0.984685246

0.246039954

0.924634238

0.292351992

0.796971217

0.292351992

0.787420402

0.096911657

0.749663357

0.099486635

0.679232994

0.292351992

0.597363001

0.157754405

Table S3. Primers used in this study.
Primer
mactin_F
mactin_R
flaB_F
flaB_R
cDNA_F
cDNA_R

Sequence
AGCGGGAAATCGTGCGTG
CAGGGTACATGGTGGTGCC
TTCAATCAGGTAACGGCACA
GACGCTTGAGACCCTGAAAG
CTGTTATTGCTAGCGTTTTAGCA
GCCACCAGAAGCGGCCGC

File S1. Excel spreadsheet containing the numerical data for Figure panels Fig 1B and Fig 1C in
separate sheet tabs; BASEHIT scores for PGLYRP1 and corresponding Borrelia isolate
(“Borrelia PGLYRP1 Scores”); BASEHIT scores for PGLYRP1 for non-Borrelia isolates (“Nonborrelia PGLYRP1 Scores”; and list of Borrelia isolates used and corresponding species
classification (“Borrelia isolates”).
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Figure S1
hPGLYRP1
mPGLYRP1

MSRRSMLLAWALPSLLRLGAAQETEDPACCSPIVPRNEWKALASECAQHLSLPLRYVVVS
-----MLFACALLALLG--------LATSCSFIVPRSEWRALPSECSSRLGHPVRYVVIS
**:* ** :**
:.** ****.**:** ***:.:*. *:****:*
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HTAGSSCNTPASCQQQARNVQHYHMKTLGWCDVGYNFLIGEDGLVYEGRGWNFTGAHSGH
HTAGSFCNSPDSCEQQARNVQHYHKNELGWCDVAYNFLIGEDGHVYEGRGWNIKGDHTGP
***** **:* **:********** : ******.********* ********:.* *:*
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hPGLYRP1
mPGLYRP1

LWNPMSIGISFMGNYMDRVPTPQAIRAAQGLLACGVAQGALRSNYVLKGHRDVQRTLSPG
IWNPMSIGITFMGNFMDRVPAKRALRAALNLLECGVSRGFLRSNYEVKGHRDVQSTLSPG
:********:****:*****: :*:*** .** ***::* ***** :******* *****
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hPGLYRP1
mPGLYRP1

NQLYHLIQNWPHYRSP
DQLYQVIQSWEHYRE:***::**.* ***.
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Figure S2

A

Human PGLYRP1

B Mouse PGLYRP1

1 µg/ml

0.1 µg/ml

1 µg/ml

0.1 µg/ml

198

0.01 µg/ml

0.01 µg/ml

Figure S3
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Figure S7
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